id sid tid token lemma pos dti-1422 1 1 13drug 13drug NUM dti-1422 1 2 target target NOUN dti-1422 1 3 insights insight VERB dti-1422 1 4 2016:10 2016:10 NUM dti-1422 1 5 effects effect NOUN dti-1422 1 6 and and CCONJ dti-1422 1 7 safety safety NOUN dti-1422 1 8 of of ADP dti-1422 1 9 linagliptin linagliptin NOUN dti-1422 1 10 as as ADP dti-1422 1 11 an an DET dti-1422 1 12 add add VERB dti-1422 1 13 - - PUNCT dti-1422 1 14 on on ADP dti-1422 1 15 therapy therapy NOUN dti-1422 1 16 in in ADP dti-1422 1 17 advanced advanced ADJ dti-1422 1 18 - - PUNCT dti-1422 1 19 stage stage NOUN dti-1422 1 20 diabetic diabetic ADJ dti-1422 1 21 nephropathy nephropathy NOUN dti-1422 1 22 patients patient NOUN dti-1422 1 23 taking take VERB dti-1422 1 24 renin renin ADJ dti-1422 1 25 – – PUNCT dti-1422 1 26 angiotensin angiotensin NOUN dti-1422 1 27 – – PUNCT dti-1422 1 28 aldosterone aldosterone NOUN dti-1422 1 29 system system NOUN dti-1422 1 30 blockers blocker VERB dti-1422 1 31 yuichiro yuichiro NOUN dti-1422 1 32 ueda1 ueda1 NOUN dti-1422 1 33 , , PUNCT dti-1422 1 34 hiroki hiroki PROPN dti-1422 1 35 ishii1 ishii1 PROPN dti-1422 1 36 , , PUNCT dti-1422 1 37 taisuke taisuke PROPN dti-1422 1 38 kitano1 kitano1 PROPN dti-1422 1 39 , , PUNCT dti-1422 1 40 mitsutoshi mitsutoshi ADJ dti-1422 1 41 shindo1 shindo1 NOUN dti-1422 1 42 , , PUNCT dti-1422 1 43 haruhisa haruhisa ADJ dti-1422 1 44 miyazawa1 miyazawa1 NOUN dti-1422 1 45 , , PUNCT dti-1422 1 46 kiyonori kiyonori PROPN dti-1422 1 47 ito1 ito1 PROPN dti-1422 1 48 , , PUNCT dti-1422 1 49 keiji keiji PROPN dti-1422 1 50 hirai1 hirai1 PROPN dti-1422 1 51 , , PUNCT dti-1422 1 52 yoshio yoshio PROPN dti-1422 1 53 kaku1 kaku1 PROPN dti-1422 1 54 , , PUNCT dti-1422 1 55 honami honami ADJ dti-1422 1 56 mori1 mori1 NOUN dti-1422 1 57 , , PUNCT dti-1422 1 58 taro taro NOUN dti-1422 1 59 hoshino1 hoshino1 PROPN dti-1422 1 60 , , PUNCT dti-1422 1 61 susumu susumu PROPN dti-1422 1 62 ookawara1 ookawara1 PROPN dti-1422 1 63 , , PUNCT dti-1422 1 64 masafumi masafumi PROPN dti-1422 1 65 kakei2 kakei2 PROPN dti-1422 1 66 , , PUNCT dti-1422 1 67 kaoru kaoru PROPN dti-1422 1 68 tabei3 tabei3 PROPN dti-1422 1 69 and and CCONJ dti-1422 1 70 yoshiyuki yoshiyuki PROPN dti-1422 1 71 morishita1 morishita1 NOUN dti-1422 1 72 1division 1division NUM dti-1422 1 73 of of ADP dti-1422 1 74 nephrology nephrology NOUN dti-1422 1 75 , , PUNCT dti-1422 1 76 2division 2division NUM dti-1422 1 77 of of ADP dti-1422 1 78 endocrinology endocrinology NOUN dti-1422 1 79 and and CCONJ dti-1422 1 80 metabolism metabolism NOUN dti-1422 1 81 , , PUNCT dti-1422 1 82 first first ADJ dti-1422 1 83 department department NOUN dti-1422 1 84 of of ADP dti-1422 1 85 integrated integrate VERB dti-1422 1 86 medicine medicine NOUN dti-1422 1 87 , , PUNCT dti-1422 1 88 saitama saitama PROPN dti-1422 1 89 medical medical ADJ dti-1422 1 90 center center NOUN dti-1422 1 91 , , PUNCT dti-1422 1 92 jichi jichi ADJ dti-1422 1 93     SPACE dti-1422 1 94 medial medial ADJ dti-1422 1 95 university university NOUN dti-1422 1 96 , , PUNCT dti-1422 1 97 saitama saitama PROPN dti-1422 1 98 , , PUNCT dti-1422 1 99 japan japan PROPN dti-1422 1 100 . . PUNCT dti-1422 2 1 3minamiuonuma 3minamiuonuma NUM dti-1422 2 2 hospital hospital NOUN dti-1422 2 3 , , PUNCT dti-1422 2 4 niigata niigata PROPN dti-1422 2 5 , , PUNCT dti-1422 2 6 japan japan PROPN dti-1422 2 7 . . PUNCT dti-1422 3 1 abstr abstr PROPN dti-1422 3 2 act act PROPN dti-1422 3 3 background background NOUN dti-1422 3 4 : : PUNCT dti-1422 3 5 we we PRON dti-1422 3 6 investigated investigate VERB dti-1422 3 7 the the DET dti-1422 3 8 effects effect NOUN dti-1422 3 9 and and CCONJ dti-1422 3 10 safety safety NOUN dti-1422 3 11 of of ADP dti-1422 3 12 linagliptin linagliptin NOUN dti-1422 3 13 as as ADP dti-1422 3 14 an an DET dti-1422 3 15 add add VERB dti-1422 3 16 - - PUNCT dti-1422 3 17 on on ADP dti-1422 3 18 therapy therapy NOUN dti-1422 3 19 in in ADP dti-1422 3 20 patients patient NOUN dti-1422 3 21 with with ADP dti-1422 3 22 advanced advanced ADJ dti-1422 3 23 - - PUNCT dti-1422 3 24 stage stage NOUN dti-1422 3 25 diabetic diabetic ADJ dti-1422 3 26 nephropathy nephropathy NOUN dti-1422 3 27 ( ( PUNCT dti-1422 3 28 dmn dmn NOUN dti-1422 3 29 ) ) PUNCT dti-1422 3 30 taking take VERB dti-1422 3 31 renin renin ADJ dti-1422 3 32 – – PUNCT dti-1422 3 33 angiotensin angiotensin NOUN dti-1422 3 34 – – PUNCT dti-1422 3 35 aldosterone aldosterone NOUN dti-1422 3 36 system system NOUN dti-1422 3 37 ( ( PUNCT dti-1422 3 38 raas raas NOUN dti-1422 3 39 ) ) PUNCT dti-1422 3 40 blockers blocker NOUN dti-1422 3 41 . . PUNCT dti-1422 4 1 method method NOUN dti-1422 4 2 : : PUNCT dti-1422 4 3 twenty twenty NUM dti-1422 4 4 advanced advanced ADJ dti-1422 4 5 - - PUNCT dti-1422 4 6 stage stage NOUN dti-1422 4 7 dmn dmn NOUN dti-1422 4 8 patients patient NOUN dti-1422 4 9 ( ( PUNCT dti-1422 4 10 estimated estimate VERB dti-1422 4 11 glomerular glomerular ADJ dti-1422 4 12 filtration filtration NOUN dti-1422 4 13 rate rate NOUN dti-1422 4 14 ( ( PUNCT dti-1422 4 15 egfr egfr X dti-1422 4 16 ): ): PUNCT dti-1422 4 17 24.5 24.5 NUM dti-1422 4 18 ± ± NUM dti-1422 4 19 13.4 13.4 NUM dti-1422 4 20     SPACE dti-1422 4 21 ml ml NOUN dti-1422 4 22 / / SYM dti-1422 4 23 min/1.73 min/1.73 NOUN dti-1422 4 24     SPACE dti-1422 4 25 m2 m2 PROPN dti-1422 4 26 ) ) PUNCT dti-1422 4 27 taking take VERB dti-1422 4 28 raas raas NOUN dti-1422 4 29 blockers blocker NOUN dti-1422 4 30 were be AUX dti-1422 4 31 administered administer VERB dti-1422 4 32 5 5 NUM dti-1422 4 33     SPACE dti-1422 4 34 mg mg PROPN dti-1422 4 35 / / SYM dti-1422 4 36 day day NOUN dti-1422 4 37 linagliptin linagliptin ADJ dti-1422 4 38 for for ADP dti-1422 4 39 52 52 NUM dti-1422 4 40     SPACE dti-1422 4 41 weeks week NOUN dti-1422 4 42 . . PUNCT dti-1422 5 1 changes change NOUN dti-1422 5 2 in in ADP dti-1422 5 3 glucose glucose NOUN dti-1422 5 4 and and CCONJ dti-1422 5 5 lipid lipid NOUN dti-1422 5 6 metabolism metabolism NOUN dti-1422 5 7 and and CCONJ dti-1422 5 8 renal renal ADJ dti-1422 5 9 function function NOUN dti-1422 5 10 were be AUX dti-1422 5 11 evaluated evaluate VERB dti-1422 5 12 . . PUNCT dti-1422 6 1 results result NOUN dti-1422 6 2 : : PUNCT dti-1422 6 3 linagliptin linagliptin PROPN dti-1422 6 4 decreased decrease VERB dti-1422 6 5 glycosylated glycosylated ADJ dti-1422 6 6 hemoglobin hemoglobin NOUN dti-1422 6 7 levels level NOUN dti-1422 6 8 ( ( PUNCT dti-1422 6 9 from from ADP dti-1422 6 10 7.32 7.32 NUM dti-1422 6 11 ± ± NUM dti-1422 6 12 0.77 0.77 NUM dti-1422 6 13 % % NOUN dti-1422 6 14 to to ADP dti-1422 6 15 6.85 6.85 NUM dti-1422 6 16 ± ± NUM dti-1422 6 17 0.87 0.87 NUM dti-1422 6 18 % % NOUN dti-1422 6 19 , , PUNCT dti-1422 6 20 p p X dti-1422 6 21 , , PUNCT dti-1422 6 22 0.05 0.05 NUM dti-1422 6 23 ) ) PUNCT dti-1422 6 24 without without ADP dti-1422 6 25 changing change VERB dti-1422 6 26 fasting fast VERB dti-1422 6 27 blood blood NOUN dti-1422 6 28 glucose glucose NOUN dti-1422 6 29 levels level NOUN dti-1422 6 30 , , PUNCT dti-1422 6 31 and and CCONJ dti-1422 6 32 significantly significantly ADV dti-1422 6 33 decreased decrease VERB dti-1422 6 34 total total ADJ dti-1422 6 35 cholesterol cholesterol NOUN dti-1422 6 36 levels level NOUN dti-1422 6 37 ( ( PUNCT dti-1422 6 38 from from ADP dti-1422 6 39 189.6 189.6 NUM dti-1422 6 40 ± ± NUM dti-1422 6 41 49.0 49.0 NUM dti-1422 6 42     SPACE dti-1422 6 43 to to ADP dti-1422 6 44 170.2 170.2 NUM dti-1422 6 45 ± ± NUM dti-1422 6 46 39.2 39.2 NUM dti-1422 6 47     SPACE dti-1422 6 48 mg mg PROPN dti-1422 6 49 / / SYM dti-1422 6 50 dl dl PROPN dti-1422 6 51 , , PUNCT dti-1422 6 52 p p X dti-1422 6 53 , , PUNCT dti-1422 6 54 0.05 0.05 NUM dti-1422 6 55 ) ) PUNCT dti-1422 6 56 and and CCONJ dti-1422 6 57 low low ADJ dti-1422 6 58 - - PUNCT dti-1422 6 59 density density NOUN dti-1422 6 60 lipoprotein lipoprotein ADJ dti-1422 6 61 cholesterol cholesterol NOUN dti-1422 6 62 levels level NOUN dti-1422 6 63 ( ( PUNCT dti-1422 6 64 from from ADP dti-1422 6 65 107.1 107.1 NUM dti-1422 6 66 ± ± NUM dti-1422 6 67 32.4 32.4 NUM dti-1422 6 68     SPACE dti-1422 6 69 to to ADP dti-1422 6 70 90.2 90.2 NUM dti-1422 6 71 ± ± NUM dti-1422 6 72 31.0 31.0 NUM dti-1422 6 73     SPACE dti-1422 6 74 mg mg PROPN dti-1422 6 75 / / SYM dti-1422 6 76 dl dl PROPN dti-1422 6 77 , , PUNCT dti-1422 6 78 p p X dti-1422 6 79 , , PUNCT dti-1422 6 80 0.05 0.05 NUM dti-1422 6 81 ) ) PUNCT dti-1422 6 82 without without ADP dti-1422 6 83 changing change VERB dti-1422 6 84 high high ADJ dti-1422 6 85 - - PUNCT dti-1422 6 86 density density NOUN dti-1422 6 87 lipoprotein lipoprotein ADJ dti-1422 6 88 cholesterol cholesterol NOUN dti-1422 6 89 and and CCONJ dti-1422 6 90 triglyceride triglyceride ADJ dti-1422 6 91 levels level NOUN dti-1422 6 92 . . PUNCT dti-1422 7 1 urine urine ADJ dti-1422 7 2 protein protein NOUN dti-1422 7 3 / / SYM dti-1422 7 4 creatinine creatinine NOUN dti-1422 7 5 ratio ratio NOUN dti-1422 7 6 and and CCONJ dti-1422 7 7 annual annual ADJ dti-1422 7 8 change change NOUN dti-1422 7 9 in in ADP dti-1422 7 10 egfr egfr NOUN dti-1422 7 11 remained remain VERB dti-1422 7 12 unchanged unchanged ADJ dti-1422 7 13 . . PUNCT dti-1422 8 1 no no DET dti-1422 8 2 adverse adverse ADJ dti-1422 8 3 effects effect NOUN dti-1422 8 4 were be AUX dti-1422 8 5 observed observe VERB dti-1422 8 6 . . PUNCT dti-1422 9 1 conclusion conclusion NOUN dti-1422 9 2 : : PUNCT dti-1422 9 3 linagliptin linagliptin ADJ dti-1422 9 4 as as ADP dti-1422 9 5 an an DET dti-1422 9 6 add add VERB dti-1422 9 7 - - PUNCT dti-1422 9 8 on on ADP dti-1422 9 9 therapy therapy NOUN dti-1422 9 10 had have VERB dti-1422 9 11 beneficial beneficial ADJ dti-1422 9 12 effects effect NOUN dti-1422 9 13 on on ADP dti-1422 9 14 glucose glucose NOUN dti-1422 9 15 and and CCONJ dti-1422 9 16 lipid lipid NOUN dti-1422 9 17 metabolism metabolism NOUN dti-1422 9 18 without without ADP dti-1422 9 19 impairment impairment NOUN dti-1422 9 20 of of ADP dti-1422 9 21 renal renal ADJ dti-1422 9 22 function function NOUN dti-1422 9 23 , , PUNCT dti-1422 9 24 and and CCONJ dti-1422 9 25 did do AUX dti-1422 9 26 not not PART dti-1422 9 27 have have VERB dti-1422 9 28 any any DET dti-1422 9 29 adverse adverse ADJ dti-1422 9 30 effects effect NOUN dti-1422 9 31 in in ADP dti-1422 9 32 this this DET dti-1422 9 33 population population NOUN dti-1422 9 34 of of ADP dti-1422 9 35 patients patient NOUN dti-1422 9 36 with with ADP dti-1422 9 37 advanced advanced ADJ dti-1422 9 38 - - PUNCT dti-1422 9 39 stage stage NOUN dti-1422 9 40 dmn dmn NOUN dti-1422 9 41 taking take VERB dti-1422 9 42 raas raas NOUN dti-1422 9 43 blockers blocker NOUN dti-1422 9 44 . . PUNCT dti-1422 10 1 key key ADJ dti-1422 10 2 words word NOUN dti-1422 10 3 : : PUNCT dti-1422 10 4 linagliptin linagliptin ADJ dti-1422 10 5 , , PUNCT dti-1422 10 6 diabetic diabetic ADJ dti-1422 10 7 nephropathy nephropathy NOUN dti-1422 10 8 , , PUNCT dti-1422 10 9 renin renin ADJ dti-1422 10 10 – – PUNCT dti-1422 10 11 angiotensin angiotensin NOUN dti-1422 10 12 – – PUNCT dti-1422 10 13 aldosterone aldosterone NOUN dti-1422 10 14 system system NOUN dti-1422 10 15 blockers blocker NOUN dti-1422 10 16 , , PUNCT dti-1422 10 17 glucose glucose NOUN dti-1422 10 18 and and CCONJ dti-1422 10 19 lipid lipid NOUN dti-1422 10 20 metabolism metabolism NOUN dti-1422 10 21 , , PUNCT dti-1422 10 22 renal renal ADJ dti-1422 10 23 function function NOUN dti-1422 10 24 citation citation NOUN dti-1422 10 25 : : PUNCT dti-1422 10 26 ueda ueda PROPN dti-1422 10 27 et et PROPN dti-1422 10 28 al al PROPN dti-1422 10 29 . . PUNCT dti-1422 10 30 effects effect NOUN dti-1422 10 31 and and CCONJ dti-1422 10 32 safety safety NOUN dti-1422 10 33 of of ADP dti-1422 10 34 linagliptin linagliptin NOUN dti-1422 10 35 as as ADP dti-1422 10 36 an an DET dti-1422 10 37 add add VERB dti-1422 10 38 - - PUNCT dti-1422 10 39 on on ADP dti-1422 10 40 therapy therapy NOUN dti-1422 10 41 in in ADP dti-1422 10 42 advanced advanced ADJ dti-1422 10 43 - - PUNCT dti-1422 10 44 stage stage NOUN dti-1422 10 45 diabetic diabetic ADJ dti-1422 10 46 nephropathy nephropathy NOUN dti-1422 10 47 patients patient NOUN dti-1422 10 48 taking take VERB dti-1422 10 49 renin renin ADJ dti-1422 10 50 – – PUNCT dti-1422 10 51 angiotensin angiotensin NOUN dti-1422 10 52 – – PUNCT dti-1422 10 53 aldosterone aldosterone NOUN dti-1422 10 54 system system NOUN dti-1422 10 55 blockers blocker NOUN dti-1422 10 56 . . PUNCT dti-1422 11 1 drug drug NOUN dti-1422 11 2 target target NOUN dti-1422 11 3 insights insight NOUN dti-1422 11 4 2016:10 2016:10 NUM dti-1422 11 5 13–18 13–18 NUM dti-1422 11 6 doi:10.4137 doi:10.4137 NOUN dti-1422 11 7 / / SYM dti-1422 11 8 dti.s38339 dti.s38339 NOUN dti-1422 11 9 . . PUNCT dti-1422 12 1 type type NOUN dti-1422 12 2 : : PUNCT dti-1422 12 3 original original ADJ dti-1422 12 4 research research NOUN dti-1422 12 5 received receive VERB dti-1422 12 6 : : PUNCT dti-1422 12 7 may may AUX dti-1422 12 8 25 25 NUM dti-1422 12 9 , , PUNCT dti-1422 12 10 2016 2016 NUM dti-1422 12 11 . . PUNCT dti-1422 13 1 resubmitted resubmitte VERB dti-1422 13 2 : : PUNCT dti-1422 13 3 august august PROPN dti-1422 13 4 11 11 NUM dti-1422 13 5 , , PUNCT dti-1422 13 6 2016 2016 NUM dti-1422 13 7 . . PUNCT dti-1422 14 1 accepted accept VERB dti-1422 14 2 for for ADP dti-1422 14 3 publication publication NOUN dti-1422 14 4 : : PUNCT dti-1422 14 5 august august PROPN dti-1422 14 6 15 15 NUM dti-1422 14 7 , , PUNCT dti-1422 14 8 2016 2016 NUM dti-1422 14 9 . . PUNCT dti-1422 15 1 academic academic ADJ dti-1422 15 2 editor editor NOUN dti-1422 15 3 : : PUNCT dti-1422 15 4 anuj anuj PROPN dti-1422 15 5 chauhan chauhan PROPN dti-1422 15 6 , , PUNCT dti-1422 15 7 editor editor NOUN dti-1422 15 8 in in ADP dti-1422 15 9 chief chief ADJ dti-1422 15 10 peer peer NOUN dti-1422 15 11 review review NOUN dti-1422 15 12 : : PUNCT dti-1422 15 13 five five NUM dti-1422 15 14 peer peer NOUN dti-1422 15 15 reviewers reviewer NOUN dti-1422 15 16 contributed contribute VERB dti-1422 15 17 to to ADP dti-1422 15 18 the the DET dti-1422 15 19 peer peer NOUN dti-1422 15 20 review review NOUN dti-1422 15 21 report report NOUN dti-1422 15 22 . . PUNCT dti-1422 16 1 reviewers reviewer NOUN dti-1422 16 2 ’ ' PUNCT dti-1422 16 3 reports report NOUN dti-1422 16 4 totaled total VERB dti-1422 16 5 910 910 NUM dti-1422 16 6 words word NOUN dti-1422 16 7 , , PUNCT dti-1422 16 8 excluding exclude VERB dti-1422 16 9 any any DET dti-1422 16 10 confidential confidential ADJ dti-1422 16 11 comments comment NOUN dti-1422 16 12 to to ADP dti-1422 16 13 the the DET dti-1422 16 14 academic academic ADJ dti-1422 16 15 editor editor NOUN dti-1422 16 16 . . PUNCT dti-1422 17 1 funding funding NOUN dti-1422 17 2 : : PUNCT dti-1422 17 3 authors author NOUN dti-1422 17 4 disclose disclose VERB dti-1422 17 5 no no DET dti-1422 17 6 external external ADJ dti-1422 17 7 funding funding NOUN dti-1422 17 8 sources source NOUN dti-1422 17 9 . . PUNCT dti-1422 18 1 competing compete VERB dti-1422 18 2 interests interest NOUN dti-1422 18 3 : : PUNCT dti-1422 18 4 authors author NOUN dti-1422 18 5 disclose disclose VERB dti-1422 18 6 no no DET dti-1422 18 7 potential potential ADJ dti-1422 18 8 conflicts conflict NOUN dti-1422 18 9 of of ADP dti-1422 18 10 interest interest NOUN dti-1422 18 11 . . PUNCT dti-1422 19 1 copyright copyright NOUN dti-1422 19 2 : : PUNCT dti-1422 19 3 © © PROPN dti-1422 19 4 the the DET dti-1422 19 5 authors author NOUN dti-1422 19 6 , , PUNCT dti-1422 19 7 publisher publisher NOUN dti-1422 19 8 and and CCONJ dti-1422 19 9 licensee licensee NOUN dti-1422 19 10 libertas liberta NOUN dti-1422 19 11 academica academica PROPN dti-1422 19 12 limited limit VERB dti-1422 19 13 . . PUNCT dti-1422 20 1 this this PRON dti-1422 20 2 is be AUX dti-1422 20 3 an an DET dti-1422 20 4 open open ADJ dti-1422 20 5 - - PUNCT dti-1422 20 6 access access NOUN dti-1422 20 7 article article NOUN dti-1422 20 8 distributed distribute VERB dti-1422 20 9 under under ADP dti-1422 20 10 the the DET dti-1422 20 11 terms term NOUN dti-1422 20 12 of of ADP dti-1422 20 13 the the DET dti-1422 20 14 creative creative ADJ dti-1422 20 15 commons common NOUN dti-1422 20 16 cc cc NOUN dti-1422 20 17 - - PUNCT dti-1422 20 18 by by ADP dti-1422 20 19 - - PUNCT dti-1422 20 20 nc nc PROPN dti-1422 20 21 3.0 3.0 NUM dti-1422 20 22 license license NOUN dti-1422 20 23 . . PUNCT dti-1422 21 1 correspondence correspondence NOUN dti-1422 21 2 : : PUNCT dti-1422 21 3 ymori@jichi.ac.jp ymori@jichi.ac.jp NOUN dti-1422 21 4 paper paper NOUN dti-1422 21 5 subject subject NOUN dti-1422 21 6 to to ADP dti-1422 21 7 independent independent ADJ dti-1422 21 8 expert expert ADJ dti-1422 21 9 single single ADJ dti-1422 21 10 - - PUNCT dti-1422 21 11 blind blind ADJ dti-1422 21 12 peer peer NOUN dti-1422 21 13 review review NOUN dti-1422 21 14 . . PUNCT dti-1422 22 1 all all DET dti-1422 22 2 editorial editorial ADJ dti-1422 22 3 decisions decision NOUN dti-1422 22 4 made make VERB dti-1422 22 5 by by ADP dti-1422 22 6 independent independent ADJ dti-1422 22 7 academic academic ADJ dti-1422 22 8 editor editor NOUN dti-1422 22 9 . . PUNCT dti-1422 23 1 upon upon SCONJ dti-1422 23 2 submission submission NOUN dti-1422 23 3 manuscript manuscript NOUN dti-1422 23 4 was be AUX dti-1422 23 5 subject subject ADJ dti-1422 23 6 to to ADP dti-1422 23 7 anti anti ADJ dti-1422 23 8 - - NOUN dti-1422 23 9 plagiarism plagiarism ADJ dti-1422 23 10 scanning scanning NOUN dti-1422 23 11 . . PUNCT dti-1422 24 1 prior prior ADV dti-1422 24 2 to to ADP dti-1422 24 3 publication publication NOUN dti-1422 24 4 all all DET dti-1422 24 5 authors author NOUN dti-1422 24 6 have have AUX dti-1422 24 7 given give VERB dti-1422 24 8 signed sign VERB dti-1422 24 9 confirmation confirmation NOUN dti-1422 24 10 of of ADP dti-1422 24 11 agreement agreement NOUN dti-1422 24 12 to to ADP dti-1422 24 13 article article NOUN dti-1422 24 14 publication publication NOUN dti-1422 24 15 and and CCONJ dti-1422 24 16 compliance compliance NOUN dti-1422 24 17 with with ADP dti-1422 24 18 all all DET dti-1422 24 19 applicable applicable ADJ dti-1422 24 20 ethical ethical ADJ dti-1422 24 21 and and CCONJ dti-1422 24 22 legal legal ADJ dti-1422 24 23 requirements requirement NOUN dti-1422 24 24 , , PUNCT dti-1422 24 25 including include VERB dti-1422 24 26 the the DET dti-1422 24 27 accuracy accuracy NOUN dti-1422 24 28 of of ADP dti-1422 24 29 author author NOUN dti-1422 24 30 and and CCONJ dti-1422 24 31 contributor contributor NOUN dti-1422 24 32 information information NOUN dti-1422 24 33 , , PUNCT dti-1422 24 34 disclosure disclosure NOUN dti-1422 24 35 of of ADP dti-1422 24 36 competing compete VERB dti-1422 24 37 interests interest NOUN dti-1422 24 38 and and CCONJ dti-1422 24 39 funding funding NOUN dti-1422 24 40 sources source NOUN dti-1422 24 41 , , PUNCT dti-1422 24 42 compliance compliance NOUN dti-1422 24 43 with with ADP dti-1422 24 44 ethical ethical ADJ dti-1422 24 45 requirements requirement NOUN dti-1422 24 46 relating relate VERB dti-1422 24 47 to to ADP dti-1422 24 48 human human ADJ dti-1422 24 49 and and CCONJ dti-1422 24 50 animal animal NOUN dti-1422 24 51 study study NOUN dti-1422 24 52 participants participant NOUN dti-1422 24 53 , , PUNCT dti-1422 24 54 and and CCONJ dti-1422 24 55 compliance compliance NOUN dti-1422 24 56 with with ADP dti-1422 24 57 any any DET dti-1422 24 58 copyright copyright NOUN dti-1422 24 59 requirements requirement NOUN dti-1422 24 60 of of ADP dti-1422 24 61 third third ADJ dti-1422 24 62 parties party NOUN dti-1422 24 63 . . PUNCT dti-1422 25 1 this this DET dti-1422 25 2 journal journal NOUN dti-1422 25 3 is be AUX dti-1422 25 4 a a DET dti-1422 25 5 member member NOUN dti-1422 25 6 of of ADP dti-1422 25 7 the the DET dti-1422 25 8 committee committee NOUN dti-1422 25 9 on on ADP dti-1422 25 10 publication publication NOUN dti-1422 25 11 ethics ethic NOUN dti-1422 25 12 ( ( PUNCT dti-1422 25 13 cope cope PROPN dti-1422 25 14 ) ) PUNCT dti-1422 25 15 . . PUNCT dti-1422 26 1 provenance provenance NOUN dti-1422 26 2 : : PUNCT dti-1422 26 3 the the DET dti-1422 26 4 authors author NOUN dti-1422 26 5 were be AUX dti-1422 26 6 invited invite VERB dti-1422 26 7 to to PART dti-1422 26 8 submit submit VERB dti-1422 26 9 this this DET dti-1422 26 10 paper paper NOUN dti-1422 26 11 . . PUNCT dti-1422 27 1 published publish VERB dti-1422 27 2 by by ADP dti-1422 27 3 libertas liberta NOUN dti-1422 27 4 academica academica PROPN dti-1422 27 5 . . PUNCT dti-1422 28 1 learn learn VERB dti-1422 28 2 more more ADJ dti-1422 28 3 about about ADP dti-1422 28 4 this this DET dti-1422 28 5 journal journal NOUN dti-1422 28 6 . . PUNCT dti-1422 29 1 introduction introduction NOUN dti-1422 29 2 the the DET dti-1422 29 3 prevalence prevalence NOUN dti-1422 29 4 of of ADP dti-1422 29 5 diabetic diabetic ADJ dti-1422 29 6 nephropathy nephropathy NOUN dti-1422 29 7 ( ( PUNCT dti-1422 29 8 dmn dmn PROPN dti-1422 29 9 ) ) PUNCT dti-1422 29 10 is be AUX dti-1422 29 11 increasing increase VERB dti-1422 29 12 worldwide.1 worldwide.1 SCONJ dti-1422 29 13 dmn dmn PROPN dti-1422 29 14 is be AUX dti-1422 29 15 the the DET dti-1422 29 16 most most ADV dti-1422 29 17 common common ADJ dti-1422 29 18 cause cause NOUN dti-1422 29 19 of of ADP dti-1422 29 20 end end NOUN dti-1422 29 21 - - PUNCT dti-1422 29 22 stage stage NOUN dti-1422 29 23 renal renal NOUN dti-1422 30 1 disease.2,3 disease.2,3 PROPN dti-1422 30 2 it it PRON dti-1422 30 3 is be AUX dti-1422 30 4 also also ADV dti-1422 30 5 a a DET dti-1422 30 6 major major ADJ dti-1422 30 7 risk risk NOUN dti-1422 30 8 factor factor NOUN dti-1422 30 9 for for ADP dti-1422 30 10 the the DET dti-1422 30 11 development development NOUN dti-1422 30 12 of of ADP dti-1422 30 13 cardiovascular cardiovascular ADJ dti-1422 30 14 disease.4 disease.4 PROPN dti-1422 30 15 a a DET dti-1422 30 16 poorly poorly ADV dti-1422 30 17 controlled control VERB dti-1422 30 18 blood blood NOUN dti-1422 30 19 glucose glucose NOUN dti-1422 30 20 level level NOUN dti-1422 30 21 and and CCONJ dti-1422 30 22 hypertension hypertension NOUN dti-1422 30 23 are be AUX dti-1422 30 24 the the DET dti-1422 30 25 main main ADJ dti-1422 30 26 contributors contributor NOUN dti-1422 30 27 to to PART dti-1422 30 28 progression progression NOUN dti-1422 30 29 to to ADP dti-1422 30 30 end end VERB dti-1422 30 31 - - PUNCT dti-1422 30 32 stage stage NOUN dti-1422 30 33 renal renal ADJ dti-1422 30 34 disease disease NOUN dti-1422 30 35 and and CCONJ dti-1422 30 36 the the DET dti-1422 30 37 development development NOUN dti-1422 30 38 of of ADP dti-1422 30 39 cardiovascular cardiovascular ADJ dti-1422 30 40 disease disease NOUN dti-1422 30 41 in in ADP dti-1422 30 42 dmn.5,6 dmn.5,6 NOUN dti-1422 30 43 appropriate appropriate ADJ dti-1422 30 44 management management NOUN dti-1422 30 45 of of ADP dti-1422 30 46 blood blood NOUN dti-1422 30 47 glucose glucose NOUN dti-1422 30 48 and and CCONJ dti-1422 30 49 blood blood NOUN dti-1422 30 50 pressure pressure NOUN dti-1422 30 51 levels level NOUN dti-1422 30 52 is be AUX dti-1422 30 53 important important ADJ dti-1422 30 54 to to PART dti-1422 30 55 improve improve VERB dti-1422 30 56 the the DET dti-1422 30 57 prognosis prognosis NOUN dti-1422 30 58 of of ADP dti-1422 30 59 patients patient NOUN dti-1422 30 60 with with ADP dti-1422 30 61 dmn.7–9 dmn.7–9 ADJ dti-1422 30 62 renin renin ADJ dti-1422 30 63 – – PUNCT dti-1422 30 64 angiotensin angiotensin NOUN dti-1422 30 65 – – PUNCT dti-1422 30 66 aldosterone aldosterone NOUN dti-1422 30 67 system system NOUN dti-1422 30 68 ( ( PUNCT dti-1422 30 69 raas raas NOUN dti-1422 30 70 ) ) PUNCT dti-1422 30 71 blockers blocker NOUN dti-1422 30 72 are be AUX dti-1422 30 73 used use VERB dti-1422 30 74 as as ADP dti-1422 30 75 first first ADJ dti-1422 30 76 - - PUNCT dti-1422 30 77 line line NOUN dti-1422 30 78 agents agent NOUN dti-1422 30 79 for for ADP dti-1422 30 80 blood blood NOUN dti-1422 30 81 pressure pressure NOUN dti-1422 30 82 control control NOUN dti-1422 30 83 in in ADP dti-1422 30 84 dmn dmn PROPN dti-1422 30 85 patients patient NOUN dti-1422 30 86 . . PUNCT dti-1422 31 1 they they PRON dti-1422 31 2 have have AUX dti-1422 31 3 been be AUX dti-1422 31 4 reported report VERB dti-1422 31 5 to to PART dti-1422 31 6 decrease decrease VERB dti-1422 31 7 blood blood NOUN dti-1422 31 8 pressure pressure NOUN dti-1422 31 9 and and CCONJ dti-1422 31 10 have have VERB dti-1422 31 11 beneficial beneficial ADJ dti-1422 31 12 nephroprotective nephroprotective ADJ dti-1422 31 13 and and CCONJ dti-1422 31 14 cardioprotective cardioprotective ADJ dti-1422 31 15 effects.10–12 effects.10–12 NOUN dti-1422 31 16 for for ADP dti-1422 31 17 blood blood NOUN dti-1422 31 18 glucose glucose NOUN dti-1422 31 19 control control NOUN dti-1422 31 20 , , PUNCT dti-1422 31 21 although although SCONJ dti-1422 31 22 many many ADJ dti-1422 31 23 kinds kind NOUN dti-1422 31 24 of of ADP dti-1422 31 25 hypoglycemic hypoglycemic ADJ dti-1422 31 26 agents agent NOUN dti-1422 31 27 have have AUX dti-1422 31 28 been be AUX dti-1422 31 29 developed develop VERB dti-1422 31 30 , , PUNCT dti-1422 31 31 most most ADJ dti-1422 31 32 can can AUX dti-1422 31 33 not not PART dti-1422 31 34 be be AUX dti-1422 31 35 used use VERB dti-1422 31 36 in in ADP dti-1422 31 37 dmn dmn PROPN dti-1422 31 38 patients patient NOUN dti-1422 31 39 with with ADP dti-1422 31 40 decreased decrease VERB dti-1422 31 41 renal renal ADJ dti-1422 31 42 function function NOUN dti-1422 31 43 because because SCONJ dti-1422 31 44 they they PRON dti-1422 31 45 have have AUX dti-1422 31 46 diminished diminish VERB dti-1422 31 47 elimination elimination NOUN dti-1422 31 48 by by ADP dti-1422 31 49 the the DET dti-1422 31 50 kidneys kidney NOUN dti-1422 31 51 , , PUNCT dti-1422 31 52 and and CCONJ dti-1422 31 53 may may AUX dti-1422 31 54 cause cause VERB dti-1422 31 55 unfavorable unfavorable ADJ dti-1422 31 56 side side NOUN dti-1422 31 57 effects effect NOUN dti-1422 31 58 . . PUNCT dti-1422 32 1 dipeptidyl dipeptidyl AUX dti-1422 32 2 peptidase-4 peptidase-4 NUM dti-1422 32 3 ( ( PUNCT dti-1422 32 4 dpp-4 dpp-4 X dti-1422 32 5 ) ) PUNCT dti-1422 32 6 inhibitors inhibitor NOUN dti-1422 32 7 decrease decrease VERB dti-1422 32 8 blood blood NOUN dti-1422 32 9 glucose glucose NOUN dti-1422 32 10 by by ADP dti-1422 32 11 inhibiting inhibit VERB dti-1422 32 12 the the DET dti-1422 32 13 degradation degradation NOUN dti-1422 32 14 of of ADP dti-1422 32 15 glucagon glucagon NOUN dti-1422 32 16 - - PUNCT dti-1422 32 17 like like ADJ dti-1422 32 18 peptide peptide NOUN dti-1422 32 19 ( ( PUNCT dti-1422 32 20 glp-1 glp-1 NOUN dti-1422 32 21 ) ) PUNCT dti-1422 32 22 , , PUNCT dti-1422 32 23 which which PRON dti-1422 32 24 enhances enhance VERB dti-1422 32 25 insulin insulin NOUN dti-1422 32 26 secretion secretion NOUN dti-1422 32 27 from from ADP dti-1422 32 28 β β NOUN dti-1422 32 29 - - NOUN dti-1422 32 30 cells cell NOUN dti-1422 32 31 and and CCONJ dti-1422 32 32 decreases decrease VERB dti-1422 32 33 glucagon glucagon NOUN dti-1422 32 34 secretion secretion NOUN dti-1422 32 35 from from ADP dti-1422 32 36 α α NOUN dti-1422 32 37 - - NOUN dti-1422 32 38 cells cell NOUN dti-1422 32 39 of of ADP dti-1422 32 40 the the DET dti-1422 32 41 pancreas.13,14 pancreas.13,14 NOUN dti-1422 32 42 among among ADP dti-1422 32 43 dpp-4 dpp-4 ADJ dti-1422 32 44 inhibitors inhibitor NOUN dti-1422 32 45 , , PUNCT dti-1422 32 46 linagliptin linagliptin PROPN dti-1422 32 47 can can AUX dti-1422 32 48 be be AUX dti-1422 32 49 used use VERB dti-1422 32 50 for for ADP dti-1422 32 51 blood blood NOUN dti-1422 32 52 glucose glucose NOUN dti-1422 32 53 control control NOUN dti-1422 32 54 in in ADP dti-1422 32 55 patients patient NOUN dti-1422 32 56 with with ADP dti-1422 32 57 impaired impaired ADJ dti-1422 32 58 renal renal ADJ dti-1422 32 59 function function NOUN dti-1422 32 60 without without ADP dti-1422 32 61 any any DET dti-1422 32 62 dose dose NOUN dti-1422 32 63 adjustment adjustment NOUN dti-1422 32 64 because because SCONJ dti-1422 32 65 it it PRON dti-1422 32 66 is be AUX dti-1422 32 67 mostly mostly ADV dti-1422 32 68 metabolized metabolize VERB dti-1422 32 69 by by ADP dti-1422 32 70 the the DET dti-1422 32 71 liver.15,16 liver.15,16 NOUN dti-1422 32 72 several several ADJ dti-1422 32 73 clinical clinical ADJ dti-1422 32 74 studies study NOUN dti-1422 32 75 have have AUX dti-1422 32 76 reported report VERB dti-1422 32 77 that that SCONJ dti-1422 32 78 linagliptin linagliptin PROPN dti-1422 32 79 improves improve VERB dti-1422 32 80 glucose glucose NOUN dti-1422 32 81 metabolism metabolism NOUN dti-1422 32 82 in in ADP dti-1422 32 83 patients patient NOUN dti-1422 32 84 with with ADP dti-1422 32 85 varying vary VERB dti-1422 32 86 degrees degree NOUN dti-1422 32 87 of of ADP dti-1422 32 88 renal renal ADJ dti-1422 32 89 function function NOUN dti-1422 32 90 , , PUNCT dti-1422 32 91 either either CCONJ dti-1422 32 92 as as ADP dti-1422 32 93 a a DET dti-1422 32 94 monotherapy monotherapy NOUN dti-1422 32 95 or or CCONJ dti-1422 32 96 in in ADP dti-1422 32 97 combination combination NOUN dti-1422 32 98 with with ADP dti-1422 32 99 other other ADJ dti-1422 32 100 hypoglycemic hypoglycemic ADJ dti-1422 32 101 agents.17–23 agents.17–23 DET dti-1422 32 102 linagliptin linagliptin NOUN dti-1422 32 103 has have AUX dti-1422 32 104 also also ADV dti-1422 32 105 been be AUX dti-1422 32 106 reported report VERB dti-1422 32 107 to to PART dti-1422 32 108 have have VERB dti-1422 32 109 beneficial beneficial ADJ dti-1422 32 110 effects effect NOUN dti-1422 32 111 on on ADP dti-1422 32 112 lipid lipid ADJ dti-1422 32 113 metabolism metabolism NOUN dti-1422 32 114 and and CCONJ dti-1422 32 115 nephroprotective nephroprotective ADJ dti-1422 32 116 effects.22,23 effects.22,23 NOUN dti-1422 32 117 this this PRON dti-1422 32 118 suggests suggest VERB dti-1422 32 119 that that SCONJ dti-1422 32 120 linagliptin linagliptin ADJ dti-1422 32 121 as as ADP dti-1422 32 122 an an DET dti-1422 32 123 add add VERB dti-1422 32 124 - - PUNCT dti-1422 32 125 on on ADP dti-1422 32 126 therapy therapy NOUN dti-1422 32 127 in in ADP dti-1422 32 128 dmn dmn PROPN dti-1422 32 129 patients patient NOUN dti-1422 32 130 taking take VERB dti-1422 32 131 raas raas NOUN dti-1422 32 132 blockers blocker NOUN dti-1422 32 133 may may AUX dti-1422 32 134 show show VERB dti-1422 32 135 advantages advantage NOUN dti-1422 32 136 in in ADP dti-1422 32 137 the the DET dti-1422 32 138 management management NOUN dti-1422 32 139 of of ADP dti-1422 32 140 dmn dmn PROPN dti-1422 32 141 . . PROPN dti-1422 32 142 journal journal PROPN dti-1422 32 143 name name PROPN dti-1422 32 144 : : PUNCT dti-1422 32 145 drug drug NOUN dti-1422 32 146 target target NOUN dti-1422 32 147 insights insight NOUN dti-1422 32 148 journal journal NOUN dti-1422 32 149 type type NOUN dti-1422 32 150 : : PUNCT dti-1422 32 151 original original ADJ dti-1422 32 152 research research NOUN dti-1422 32 153 year year NOUN dti-1422 32 154 : : PUNCT dti-1422 32 155 2016 2016 NUM dti-1422 32 156 volume volume NOUN dti-1422 32 157 : : PUNCT dti-1422 32 158 10 10 NUM dti-1422 32 159 running run VERB dti-1422 32 160 head head NOUN dti-1422 32 161 verso verso ADJ dti-1422 32 162 : : PUNCT dti-1422 32 163 ueda ueda PROPN dti-1422 32 164 et et PROPN dti-1422 32 165 al al PROPN dti-1422 32 166 running run VERB dti-1422 32 167 head head NOUN dti-1422 32 168 recto recto NOUN dti-1422 32 169 : : PUNCT dti-1422 32 170 effects effect NOUN dti-1422 32 171 and and CCONJ dti-1422 32 172 safety safety NOUN dti-1422 32 173 of of ADP dti-1422 32 174 linagliptin linagliptin NOUN dti-1422 32 175 as as ADP dti-1422 32 176 an an DET dti-1422 32 177 add add VERB dti-1422 32 178 - - PUNCT dti-1422 32 179 on on ADP dti-1422 32 180 therapy therapy NOUN dti-1422 32 181 http://www.la-press.com/drug-target-insights-journal-j23 http://www.la-press.com/drug-target-insights-journal-j23 PROPN dti-1422 32 182 http://www.la-press.com http://www.la-press.com X dti-1422 32 183 http://dx.doi.org/10.4137/dti.s38339 http://dx.doi.org/10.4137/dti.s38339 PROPN dti-1422 32 184 http://creativecommons.org/licenses/by-nc/3.0/ http://creativecommons.org/licenses/by-nc/3.0/ PROPN dti-1422 32 185 http://creativecommons.org/licenses/by-nc/3.0/ http://creativecommons.org/licenses/by-nc/3.0/ PROPN dti-1422 32 186 mailto:ymori@jichi.ac.jp mailto:ymori@jichi.ac.jp PROPN dti-1422 32 187 http://www.la-press.com http://www.la-press.com X dti-1422 32 188 http://www.la-press.com/drug-target-insights-journal-j23 http://www.la-press.com/drug-target-insights-journal-j23 PROPN dti-1422 32 189 ueda ueda PROPN dti-1422 32 190 et et PROPN dti-1422 32 191 al al PROPN dti-1422 32 192 14 14 NUM dti-1422 32 193 drug drug NOUN dti-1422 32 194 target target NOUN dti-1422 32 195 insights insight NOUN dti-1422 32 196 2016:10 2016:10 NUM dti-1422 32 197 only only ADV dti-1422 32 198 a a DET dti-1422 32 199 few few ADJ dti-1422 32 200 experimental experimental ADJ dti-1422 32 201 and and CCONJ dti-1422 32 202 clinical clinical ADJ dti-1422 32 203 studies study NOUN dti-1422 32 204 have have AUX dti-1422 32 205 been be AUX dti-1422 32 206 reported report VERB dti-1422 32 207 on on ADP dti-1422 32 208 the the DET dti-1422 32 209 effects effect NOUN dti-1422 32 210 of of ADP dti-1422 32 211 linagliptin linagliptin ADJ dti-1422 32 212 in in ADP dti-1422 32 213 combination combination NOUN dti-1422 32 214 with with ADP dti-1422 32 215 raas raas NOUN dti-1422 32 216 blockers blocker NOUN dti-1422 32 217 in in ADP dti-1422 32 218 dmn.22,24 dmn.22,24 PROPN dti-1422 32 219 also also ADV dti-1422 32 220 , , PUNCT dti-1422 32 221 the the DET dti-1422 32 222 effects effect NOUN dti-1422 32 223 and and CCONJ dti-1422 32 224 safety safety NOUN dti-1422 32 225 of of ADP dti-1422 32 226 linagliptin linagliptin ADJ dti-1422 32 227 in in ADP dti-1422 32 228 advanced advanced ADJ dti-1422 32 229 - - PUNCT dti-1422 32 230 stage stage NOUN dti-1422 32 231 dmn dmn NOUN dti-1422 32 232 patients patient NOUN dti-1422 32 233 taking take VERB dti-1422 32 234 raas raas NOUN dti-1422 32 235 blockers blocker NOUN dti-1422 32 236 have have AUX dti-1422 32 237 not not PART dti-1422 32 238 been be AUX dti-1422 32 239 fully fully ADV dti-1422 32 240 determined determine VERB dti-1422 32 241 . . PUNCT dti-1422 33 1 in in ADP dti-1422 33 2 this this DET dti-1422 33 3 study study NOUN dti-1422 33 4 , , PUNCT dti-1422 33 5 we we PRON dti-1422 33 6 investigated investigate VERB dti-1422 33 7 the the DET dti-1422 33 8 effects effect NOUN dti-1422 33 9 and and CCONJ dti-1422 33 10 safety safety NOUN dti-1422 33 11 of of ADP dti-1422 33 12 linagliptin linagliptin NOUN dti-1422 33 13 as as ADP dti-1422 33 14 an an DET dti-1422 33 15 add add VERB dti-1422 33 16 - - PUNCT dti-1422 33 17 on on ADP dti-1422 33 18 therapy therapy NOUN dti-1422 33 19 in in ADP dti-1422 33 20 advanced advanced ADJ dti-1422 33 21 - - PUNCT dti-1422 33 22 stage stage NOUN dti-1422 33 23 dmn dmn NOUN dti-1422 33 24 patients patient NOUN dti-1422 33 25 taking take VERB dti-1422 33 26 raas raas NOUN dti-1422 33 27 blockers blocker NOUN dti-1422 33 28 . . PUNCT dti-1422 34 1 participants participant NOUN dti-1422 34 2 and and CCONJ dti-1422 34 3 methods method NOUN dti-1422 34 4 ethical ethical ADJ dti-1422 34 5 considerations consideration NOUN dti-1422 34 6 . . PUNCT dti-1422 35 1 this this DET dti-1422 35 2 study study NOUN dti-1422 35 3 was be AUX dti-1422 35 4 performed perform VERB dti-1422 35 5 in in ADP dti-1422 35 6 accordance accordance NOUN dti-1422 35 7 with with ADP dti-1422 35 8 the the DET dti-1422 35 9 ethical ethical ADJ dti-1422 35 10 principles principle NOUN dti-1422 35 11 contained contain VERB dti-1422 35 12 in in ADP dti-1422 35 13 the the DET dti-1422 35 14 declaration declaration NOUN dti-1422 35 15 of of ADP dti-1422 35 16 helsinki helsinki PROPN dti-1422 35 17 and and CCONJ dti-1422 35 18 was be AUX dti-1422 35 19 approved approve VERB dti-1422 35 20 by by ADP dti-1422 35 21 the the DET dti-1422 35 22 ethics ethic NOUN dti-1422 35 23 committee committee PROPN dti-1422 35 24 of of ADP dti-1422 35 25 saitama saitama PROPN dti-1422 35 26 medical medical ADJ dti-1422 35 27 center center NOUN dti-1422 35 28 , , PUNCT dti-1422 35 29 jichi jichi PROPN dti-1422 35 30 medical medical PROPN dti-1422 35 31 university university PROPN dti-1422 35 32 . . PUNCT dti-1422 36 1 written write VERB dti-1422 36 2 informed informed ADJ dti-1422 36 3 consent consent NOUN dti-1422 36 4 was be AUX dti-1422 36 5 obtained obtain VERB dti-1422 36 6 from from ADP dti-1422 36 7 all all DET dti-1422 36 8 patients patient NOUN dti-1422 36 9 . . PUNCT dti-1422 37 1 patients patient NOUN dti-1422 37 2 . . PUNCT dti-1422 38 1 between between ADP dti-1422 38 2 march march PROPN dti-1422 38 3 2013 2013 NUM dti-1422 38 4 and and CCONJ dti-1422 38 5 july july PROPN dti-1422 38 6 2014 2014 NUM dti-1422 38 7 , , PUNCT dti-1422 38 8 30 30 NUM dti-1422 38 9 patients patient NOUN dti-1422 38 10 were be AUX dti-1422 38 11 enrolled enrol VERB dti-1422 38 12 in in ADP dti-1422 38 13 the the DET dti-1422 38 14 study study NOUN dti-1422 38 15 . . PUNCT dti-1422 39 1 inclusion inclusion NOUN dti-1422 39 2 criteria criterion NOUN dti-1422 39 3 were be AUX dti-1422 39 4 as as SCONJ dti-1422 39 5 follows follow VERB dti-1422 39 6 : : PUNCT dti-1422 39 7 .20 .20 NUM dti-1422 39 8     SPACE dti-1422 39 9 years year NOUN dti-1422 39 10 of of ADP dti-1422 39 11 age age NOUN dti-1422 39 12 , , PUNCT dti-1422 39 13 suffering suffer VERB dti-1422 39 14 from from ADP dti-1422 39 15 type type NOUN dti-1422 39 16 2 2 NUM dti-1422 39 17 dmn dmn NOUN dti-1422 39 18 , , PUNCT dti-1422 39 19 dmn dmn PROPN dti-1422 39 20 with with ADP dti-1422 39 21 an an DET dti-1422 39 22 estimated estimate VERB dti-1422 39 23 glomerular glomerular ADJ dti-1422 39 24 filtration filtration NOUN dti-1422 39 25 rate rate NOUN dti-1422 39 26 ( ( PUNCT dti-1422 39 27 egfr egfr X dti-1422 39 28 ) ) PUNCT dti-1422 39 29     SPACE dti-1422 39 30 # # NOUN dti-1422 39 31 60 60 NUM dti-1422 39 32 ( ( PUNCT dti-1422 39 33 ml ml PROPN dti-1422 39 34 / / SYM dti-1422 39 35 min/1.73 min/1.73 NOUN dti-1422 39 36     SPACE dti-1422 39 37 m2 m2 NOUN dti-1422 39 38 ) ) PUNCT dti-1422 39 39 , , PUNCT dti-1422 39 40 urine urine ADJ dti-1422 39 41 protein protein NOUN dti-1422 39 42 / / SYM dti-1422 39 43 creatinine creatinine NOUN dti-1422 39 44 ratio ratio NOUN dti-1422 39 45 ( ( PUNCT dti-1422 39 46 uacr uacr INTJ dti-1422 39 47 ) ) PUNCT dti-1422 39 48 . . PUNCT dti-1422 40 1 0.15 0.15 NUM dti-1422 40 2 ( ( PUNCT dti-1422 40 3 g g NOUN dti-1422 40 4 / / SYM dti-1422 40 5 g g NOUN dti-1422 40 6 cr cr PROPN dti-1422 40 7 ) ) PUNCT dti-1422 40 8 , , PUNCT dti-1422 40 9 and and CCONJ dti-1422 40 10 taking take VERB dti-1422 40 11 angiotensin angiotensin NOUN dti-1422 40 12 iireceptor iireceptor NOUN dti-1422 40 13 blockers blocker NOUN dti-1422 40 14 or or CCONJ dti-1422 40 15 angiotensin angiotensin NOUN dti-1422 40 16 - - PUNCT dti-1422 40 17 converting convert VERB dti-1422 40 18 enzyme enzyme NOUN dti-1422 40 19 inhibitors inhibitor NOUN dti-1422 40 20 . . PUNCT dti-1422 41 1 exclusion exclusion NOUN dti-1422 41 2 criteria criterion NOUN dti-1422 41 3 were be AUX dti-1422 41 4 patients patient NOUN dti-1422 41 5 with with ADP dti-1422 41 6 type type NOUN dti-1422 41 7 1 1 NUM dti-1422 41 8 diabetes diabetes NOUN dti-1422 41 9 mellitus mellitus NOUN dti-1422 41 10 or or CCONJ dti-1422 41 11 secondary secondary ADJ dti-1422 41 12 diabetes diabetes NOUN dti-1422 41 13 mellitus mellitus NOUN dti-1422 41 14 , , PUNCT dti-1422 41 15 history history NOUN dti-1422 41 16 of of ADP dti-1422 41 17 stroke stroke NOUN dti-1422 41 18 or or CCONJ dti-1422 41 19 coronary coronary ADJ dti-1422 41 20 heart heart NOUN dti-1422 41 21 disease disease NOUN dti-1422 41 22 , , PUNCT dti-1422 41 23 patients patient NOUN dti-1422 41 24 with with ADP dti-1422 41 25 malignancy malignancy NOUN dti-1422 41 26 , , PUNCT dti-1422 41 27 severe severe ADJ dti-1422 41 28 infection infection NOUN dti-1422 41 29 , , PUNCT dti-1422 41 30 urinary urinary ADJ dti-1422 41 31 stones stone NOUN dti-1422 41 32 , , PUNCT dti-1422 41 33 steroid steroid NOUN dti-1422 41 34 therapy therapy NOUN dti-1422 41 35 , , PUNCT dti-1422 41 36 pregnant pregnant ADJ dti-1422 41 37 or or CCONJ dti-1422 41 38 lactating lactate VERB dti-1422 41 39 women woman NOUN dti-1422 41 40 , , PUNCT dti-1422 41 41 and and CCONJ dti-1422 41 42 patients patient NOUN dti-1422 41 43 with with ADP dti-1422 41 44 an an DET dti-1422 41 45 allergy allergy NOUN dti-1422 41 46 to to ADP dti-1422 41 47 linagliptin linagliptin PROPN dti-1422 41 48 . . PUNCT dti-1422 42 1 study study NOUN dti-1422 42 2 protocol protocol NOUN dti-1422 42 3 . . PUNCT dti-1422 43 1 a a DET dti-1422 43 2 diagram diagram NOUN dti-1422 43 3 of of ADP dti-1422 43 4 the the DET dti-1422 43 5 study study NOUN dti-1422 43 6 design design NOUN dti-1422 43 7 is be AUX dti-1422 43 8 shown show VERB dti-1422 43 9 in in ADP dti-1422 43 10 figure figure NOUN dti-1422 43 11 1 1 NUM dti-1422 43 12 . . PUNCT dti-1422 44 1 the the DET dti-1422 44 2 study study NOUN dti-1422 44 3 was be AUX dti-1422 44 4 a a DET dti-1422 44 5 52 52 NUM dti-1422 44 6 - - PUNCT dti-1422 44 7 week week NOUN dti-1422 44 8 , , PUNCT dti-1422 44 9 single single ADJ dti-1422 44 10 - - PUNCT dti-1422 44 11 center center NOUN dti-1422 44 12 , , PUNCT dti-1422 44 13 prospective prospective ADJ dti-1422 44 14 study study NOUN dti-1422 44 15 . . PUNCT dti-1422 45 1 all all DET dti-1422 45 2 eligible eligible ADJ dti-1422 45 3 patients patient NOUN dti-1422 45 4 were be AUX dti-1422 45 5 administered administer VERB dti-1422 45 6 linagliptin linagliptin ADJ dti-1422 45 7 5 5 NUM dti-1422 45 8     SPACE dti-1422 45 9 mg mg NOUN dti-1422 45 10 orally orally ADV dti-1422 45 11 in in ADP dti-1422 45 12 the the DET dti-1422 45 13 morning morning NOUN dti-1422 45 14 once once ADV dti-1422 45 15 daily daily ADV dti-1422 45 16 as as ADP dti-1422 45 17 an an DET dti-1422 45 18 add add NOUN dti-1422 45 19 - - PUNCT dti-1422 45 20 on on ADP dti-1422 45 21 to to ADP dti-1422 45 22 existing exist VERB dti-1422 45 23 drugs drug NOUN dti-1422 45 24 including include VERB dti-1422 45 25 raas raas NOUN dti-1422 45 26 blockers blocker NOUN dti-1422 45 27 , , PUNCT dti-1422 45 28 hypolipidemic hypolipidemic ADJ dti-1422 45 29 drugs drug NOUN dti-1422 45 30 , , PUNCT dti-1422 45 31 and and CCONJ dti-1422 45 32 anti anti ADJ dti-1422 45 33 - - ADJ dti-1422 45 34 hyperglycemic hyperglycemic ADJ dti-1422 45 35 agents agent NOUN dti-1422 45 36 but but CCONJ dti-1422 45 37 not not PART dti-1422 45 38 dpp-4 dpp-4 ADV dti-1422 45 39 inhibitors inhibitor NOUN dti-1422 45 40 . . PUNCT dti-1422 46 1 six six NUM dti-1422 46 2 patients patient NOUN dti-1422 46 3 were be AUX dti-1422 46 4 changed change VERB dti-1422 46 5 from from ADP dti-1422 46 6 an an DET dti-1422 46 7 existing exist VERB dti-1422 46 8 dpp-4 dpp-4 PUNCT dti-1422 46 9 inhibitor inhibitor NOUN dti-1422 46 10 ( ( PUNCT dti-1422 46 11 vildagliptin vildagliptin NOUN dti-1422 46 12 ) ) PUNCT dti-1422 46 13 to to ADP dti-1422 46 14 5 5 NUM dti-1422 46 15     SPACE dti-1422 46 16 mg mg PROPN dti-1422 46 17 / / SYM dti-1422 46 18 day day NOUN dti-1422 46 19 linagliptin linagliptin ADV dti-1422 46 20 . . PUNCT dti-1422 47 1 the the DET dti-1422 47 2 dosage dosage NOUN dti-1422 47 3 of of ADP dti-1422 47 4 the the DET dti-1422 47 5 drugs drug NOUN dti-1422 47 6 , , PUNCT dti-1422 47 7 including include VERB dti-1422 47 8 raas raas NOUN dti-1422 47 9 blockers blocker NOUN dti-1422 47 10 , , PUNCT dti-1422 47 11 hypolipidemic hypolipidemic ADJ dti-1422 47 12 drugs drug NOUN dti-1422 47 13 , , PUNCT dti-1422 47 14 and and CCONJ dti-1422 47 15 anti anti ADJ dti-1422 47 16 - - ADJ dti-1422 47 17 hyperglycemic hyperglycemic ADJ dti-1422 47 18 agents agent NOUN dti-1422 47 19 , , PUNCT dti-1422 47 20 was be AUX dti-1422 47 21 not not PART dti-1422 47 22 changed change VERB dti-1422 47 23 during during ADP dti-1422 47 24 the the DET dti-1422 47 25 study study NOUN dti-1422 47 26 period period NOUN dti-1422 47 27 . . PUNCT dti-1422 48 1 changes change NOUN dti-1422 48 2 in in ADP dti-1422 48 3 glucose glucose NOUN dti-1422 48 4 metabolism metabolism NOUN dti-1422 48 5 [ [ X dti-1422 48 6 fasting fast VERB dti-1422 48 7 blood blood NOUN dti-1422 48 8 glucose glucose NOUN dti-1422 48 9 and and CCONJ dti-1422 48 10 glycosylated glycosylated ADJ dti-1422 48 11 hemoglobin hemoglobin NOUN dti-1422 48 12 ( ( PUNCT dti-1422 48 13 hba1c hba1c PROPN dti-1422 48 14 ) ) PUNCT dti-1422 48 15 ] ] PUNCT dti-1422 48 16 and and CCONJ dti-1422 48 17 lipid lipid ADJ dti-1422 48 18 metabolism metabolism NOUN dti-1422 49 1 [ [ X dti-1422 49 2 total total ADJ dti-1422 49 3 cholesterol cholesterol NOUN dti-1422 49 4 , , PUNCT dti-1422 49 5 low low ADJ dti-1422 49 6 - - PUNCT dti-1422 49 7 density density NOUN dti-1422 49 8 lipoprotein lipoprotein NOUN dti-1422 49 9 ( ( PUNCT dti-1422 49 10 ldl)-cholesterol ldl)-cholesterol PROPN dti-1422 49 11 , , PUNCT dti-1422 49 12 high high ADJ dti-1422 49 13 - - PUNCT dti-1422 49 14 density density NOUN dti-1422 49 15 lipoprotein lipoprotein NOUN dti-1422 49 16 ( ( PUNCT dti-1422 49 17 hdl)-cholesterol hdl)-cholesterol NOUN dti-1422 49 18 , , PUNCT dti-1422 49 19 and and CCONJ dti-1422 49 20 triglycerides triglyceride NOUN dti-1422 49 21 ] ] PUNCT dti-1422 49 22 were be AUX dti-1422 49 23 evaluated evaluate VERB dti-1422 49 24 at at ADP dti-1422 49 25 baseline baseline NOUN dti-1422 49 26 and and CCONJ dti-1422 49 27 at at ADP dti-1422 49 28 12 12 NUM dti-1422 49 29 , , PUNCT dti-1422 49 30 24 24 NUM dti-1422 49 31 , , PUNCT dti-1422 49 32 38 38 NUM dti-1422 49 33 , , PUNCT dti-1422 49 34 and and CCONJ dti-1422 49 35 52 52 NUM dti-1422 49 36     SPACE dti-1422 49 37 weeks week NOUN dti-1422 49 38 after after ADP dti-1422 49 39 administration administration NOUN dti-1422 49 40 of of ADP dti-1422 49 41 linagliptin linagliptin PROPN dti-1422 49 42 . . PUNCT dti-1422 50 1 changes change NOUN dti-1422 50 2 in in ADP dti-1422 50 3 uacr uacr PROPN dti-1422 50 4 were be AUX dti-1422 50 5 also also ADV dti-1422 50 6 measured measure VERB dti-1422 50 7 at at ADP dti-1422 50 8 the the DET dti-1422 50 9 same same ADJ dti-1422 50 10 time time NOUN dti-1422 50 11 points point NOUN dti-1422 50 12 . . PUNCT dti-1422 51 1 the the DET dti-1422 51 2 annual annual ADJ dti-1422 51 3 change change NOUN dti-1422 51 4 in in ADP dti-1422 51 5 egfr egfr NOUN dti-1422 51 6 ( ( PUNCT dti-1422 51 7 ml ml PROPN dti-1422 51 8 / / SYM dti-1422 51 9 min/1.73 min/1.73 NOUN dti-1422 51 10     SPACE dti-1422 51 11 m2 m2 PROPN dti-1422 51 12 / / SYM dti-1422 51 13 year year NOUN dti-1422 51 14 ) ) PUNCT dti-1422 51 15 was be AUX dti-1422 51 16 evaluated evaluate VERB dti-1422 51 17 before before ADP dti-1422 51 18 and and CCONJ dti-1422 51 19 after after ADP dti-1422 51 20 administration administration NOUN dti-1422 51 21 of of ADP dti-1422 51 22 linagliptin linagliptin PROPN dti-1422 51 23 . . PUNCT dti-1422 52 1 patients patient NOUN dti-1422 52 2 who who PRON dti-1422 52 3 underwent undergo VERB dti-1422 52 4 dialysis dialysis NOUN dti-1422 52 5 therapy therapy NOUN dti-1422 52 6 because because SCONJ dti-1422 52 7 of of ADP dti-1422 52 8 progression progression NOUN dti-1422 52 9 to to PART dti-1422 52 10 end end VERB dti-1422 52 11 - - PUNCT dti-1422 52 12 stage stage NOUN dti-1422 52 13 renal renal ADJ dti-1422 52 14 disease disease NOUN dti-1422 52 15 were be AUX dti-1422 52 16 removed remove VERB dti-1422 52 17 from from ADP dti-1422 52 18 the the DET dti-1422 52 19 study study NOUN dti-1422 52 20 because because SCONJ dti-1422 52 21 changes change NOUN dti-1422 52 22 in in ADP dti-1422 52 23 renal renal ADJ dti-1422 52 24 function function NOUN dti-1422 52 25 could could AUX dti-1422 52 26 not not PART dti-1422 52 27 be be AUX dti-1422 52 28 evaluated evaluate VERB dti-1422 52 29 . . PUNCT dti-1422 53 1 laboratory laboratory NOUN dti-1422 53 2 methods method NOUN dti-1422 53 3 . . PUNCT dti-1422 54 1 egfr egfr PROPN dti-1422 54 2 was be AUX dti-1422 54 3 calculated calculate VERB dti-1422 54 4 using use VERB dti-1422 54 5 a a DET dti-1422 54 6 modified modify VERB dti-1422 54 7 version version NOUN dti-1422 54 8 of of ADP dti-1422 54 9 the the DET dti-1422 54 10 modification modification NOUN dti-1422 54 11 of of ADP dti-1422 54 12 diet diet NOUN dti-1422 54 13 in in ADP dti-1422 54 14 renal renal ADJ dti-1422 54 15 disease disease NOUN dti-1422 54 16 formula formula NOUN dti-1422 54 17 of of ADP dti-1422 54 18 the the DET dti-1422 54 19 japanese japanese ADJ dti-1422 54 20 society society NOUN dti-1422 54 21 of of ADP dti-1422 54 22 nephrology nephrology NOUN dti-1422 54 23 : : PUNCT dti-1422 54 24 egfr egfr NOUN dti-1422 54 25 ( ( PUNCT dti-1422 54 26 ml ml PROPN dti-1422 54 27 / / SYM dti-1422 54 28 min/1.73 min/1.73 NOUN dti-1422 54 29     SPACE dti-1422 54 30 m2 m2 PROPN dti-1422 54 31 ) ) PUNCT dti-1422 54 32 = = SYM dti-1422 55 1 194 194 NUM dti-1422 55 2 × × NOUN dti-1422 55 3 age-0.287 age-0.287 PROPN dti-1422 55 4 × × NOUN dti-1422 55 5 serum serum NOUN dti-1422 55 6 creatinine-1.094 creatinine-1.094 X dti-1422 55 7 ( ( PUNCT dti-1422 55 8 multiplied multiply VERB dti-1422 55 9 by by ADP dti-1422 55 10 0.739 0.739 NUM dti-1422 55 11 for for SCONJ dti-1422 55 12 women).25 women).25 PROPN dti-1422 55 13 blood blood NOUN dti-1422 55 14 and and CCONJ dti-1422 55 15 urinary urinary ADJ dti-1422 55 16 parameters parameter NOUN dti-1422 55 17 were be AUX dti-1422 55 18 determined determine VERB dti-1422 55 19 by by ADP dti-1422 55 20 the the DET dti-1422 55 21 department department NOUN dti-1422 55 22 of of ADP dti-1422 55 23 clinical clinical ADJ dti-1422 55 24 laboratory laboratory NOUN dti-1422 55 25 , , PUNCT dti-1422 55 26 saitama saitama PROPN dti-1422 55 27 medical medical ADJ dti-1422 55 28 center center NOUN dti-1422 55 29 , , PUNCT dti-1422 55 30 jichi jichi PROPN dti-1422 55 31 medical medical ADJ dti-1422 55 32 university university PROPN dti-1422 55 33 . . PUNCT dti-1422 56 1 statistical statistical ADJ dti-1422 56 2 analysis analysis NOUN dti-1422 56 3 . . PUNCT dti-1422 57 1 data datum NOUN dti-1422 57 2 are be AUX dti-1422 57 3 expressed express VERB dti-1422 57 4 as as ADP dti-1422 57 5 mean mean NOUN dti-1422 57 6 ± ± NUM dti-1422 57 7 standard standard ADJ dti-1422 57 8 deviation deviation NOUN dti-1422 57 9 . . PUNCT dti-1422 58 1 repeated repeat VERB dti-1422 58 2 - - PUNCT dti-1422 58 3 measure measure NOUN dti-1422 58 4 analysis analysis NOUN dti-1422 58 5 of of ADP dti-1422 58 6 variance variance NOUN dti-1422 58 7 was be AUX dti-1422 58 8 used use VERB dti-1422 58 9 to to PART dti-1422 58 10 compare compare VERB dti-1422 58 11 continuous continuous ADJ dti-1422 58 12 data datum NOUN dti-1422 58 13 . . PUNCT dti-1422 59 1 differences difference NOUN dti-1422 59 2 with with ADP dti-1422 59 3 a a DET dti-1422 59 4 p p NOUN dti-1422 59 5 - - PUNCT dti-1422 59 6 value value NOUN dti-1422 59 7     SPACE dti-1422 59 8 , , PUNCT dti-1422 59 9     SPACE dti-1422 59 10 0.05 0.05 NUM dti-1422 59 11 were be AUX dti-1422 59 12 considered consider VERB dti-1422 59 13 statistically statistically ADV dti-1422 59 14 significant significant ADJ dti-1422 59 15 . . PUNCT dti-1422 60 1 a a DET dti-1422 60 2     SPACE dti-1422 60 3 paired pair VERB dti-1422 60 4 t t NOUN dti-1422 60 5 - - PUNCT dti-1422 60 6 test test NOUN dti-1422 60 7 was be AUX dti-1422 60 8 used use VERB dti-1422 60 9 to to PART dti-1422 60 10 compare compare VERB dti-1422 60 11 the the DET dti-1422 60 12 annual annual ADJ dti-1422 60 13 egfr egfr NOUN dti-1422 60 14 change change NOUN dti-1422 60 15 before before ADP dti-1422 60 16 and and CCONJ dti-1422 60 17 after after ADP dti-1422 60 18 administration administration NOUN dti-1422 60 19 of of ADP dti-1422 60 20 linagliptin linagliptin PROPN dti-1422 60 21 . . PUNCT dti-1422 61 1 results result VERB dti-1422 61 2 thirty thirty NUM dti-1422 61 3 patients patient NOUN dti-1422 61 4 were be AUX dti-1422 61 5 enrolled enrol VERB dti-1422 61 6 in in ADP dti-1422 61 7 the the DET dti-1422 61 8 study study NOUN dti-1422 61 9 and and CCONJ dti-1422 61 10 administered administer VERB dti-1422 61 11 linagliptin linagliptin ADJ dti-1422 61 12 ( ( PUNCT dti-1422 61 13 fig fig NOUN dti-1422 61 14 . . PUNCT dti-1422 62 1 2 2 NUM dti-1422 62 2 ) ) PUNCT dti-1422 62 3 . . PUNCT dti-1422 63 1 four four NUM dti-1422 63 2 patients patient NOUN dti-1422 63 3 were be AUX dti-1422 63 4 discontinued discontinue VERB dti-1422 63 5 because because SCONJ dti-1422 63 6 figure figure NOUN dti-1422 63 7 1 1 NUM dti-1422 63 8 . . PUNCT dti-1422 63 9 diagram diagram NOUN dti-1422 63 10 of of ADP dti-1422 63 11 study study NOUN dti-1422 63 12 design design NOUN dti-1422 63 13 . . PUNCT dti-1422 64 1 abbreviations abbreviation NOUN dti-1422 64 2 : : PUNCT dti-1422 64 3 wk wk NOUN dti-1422 64 4 , , PUNCT dti-1422 64 5 week week NOUN dti-1422 64 6 ; ; PUNCT dti-1422 64 7 hba1c hba1c PROPN dti-1422 64 8 , , PUNCT dti-1422 64 9 glycosylated glycosylated ADJ dti-1422 64 10 hemoglobin hemoglobin NOUN dti-1422 64 11 ; ; PUNCT dti-1422 64 12 ldl ldl NOUN dti-1422 64 13 , , PUNCT dti-1422 64 14 low low ADJ dti-1422 64 15 - - PUNCT dti-1422 64 16 density density NOUN dti-1422 64 17 lipoprotein lipoprotein NOUN dti-1422 64 18 ; ; PUNCT dti-1422 64 19 hdl hdl X dti-1422 64 20 , , PUNCT dti-1422 64 21 high high ADJ dti-1422 64 22 - - PUNCT dti-1422 64 23 density density NOUN dti-1422 64 24 lipoprotein lipoprotein NOUN dti-1422 64 25 ; ; PUNCT dti-1422 64 26 uacr uacr ADJ dti-1422 64 27 , , PUNCT dti-1422 64 28 urine urine ADJ dti-1422 64 29 protein protein NOUN dti-1422 64 30 / / SYM dti-1422 64 31 creatinine creatinine NOUN dti-1422 64 32 ratio ratio NOUN dti-1422 64 33 ; ; PUNCT dti-1422 64 34 egfr egfr X dti-1422 64 35 , , PUNCT dti-1422 64 36 estimated estimate VERB dti-1422 64 37 glomerular glomerular ADJ dti-1422 64 38 filtration filtration NOUN dti-1422 64 39 rate rate NOUN dti-1422 64 40 . . PUNCT dti-1422 65 1 http://www.la-press.com http://www.la-press.com X dti-1422 66 1 http://www.la-press.com/drug-target-insights-journal-j23 http://www.la-press.com/drug-target-insights-journal-j23 PROPN dti-1422 66 2 effects effect NOUN dti-1422 66 3 and and CCONJ dti-1422 66 4 safety safety NOUN dti-1422 66 5 of of ADP dti-1422 66 6 linagliptin linagliptin NOUN dti-1422 66 7 as as ADP dti-1422 66 8 an an DET dti-1422 66 9 add add VERB dti-1422 66 10 - - PUNCT dti-1422 66 11 on on ADP dti-1422 66 12 therapy therapy NOUN dti-1422 66 13 15drug 15drug PROPN dti-1422 66 14 target target NOUN dti-1422 66 15 insights insight NOUN dti-1422 66 16 2016:10 2016:10 NUM dti-1422 66 17 they they PRON dti-1422 66 18 progressed progress VERB dti-1422 66 19 to to ADP dti-1422 66 20 end end NOUN dti-1422 66 21 - - PUNCT dti-1422 66 22 stage stage NOUN dti-1422 66 23 renal renal ADJ dti-1422 66 24 disease disease NOUN dti-1422 66 25 and and CCONJ dti-1422 66 26 underwent underwent ADJ dti-1422 66 27 hemodialysis hemodialysis NOUN dti-1422 66 28 . . PUNCT dti-1422 67 1 another another DET dti-1422 67 2 two two NUM dti-1422 67 3 patients patient NOUN dti-1422 67 4 were be AUX dti-1422 67 5 discontinued discontinue VERB dti-1422 67 6 because because SCONJ dti-1422 67 7 of of ADP dti-1422 67 8 diagnoses diagnosis NOUN dti-1422 67 9 of of ADP dti-1422 67 10 colon colon NOUN dti-1422 67 11 cancer cancer NOUN dti-1422 67 12 and and CCONJ dti-1422 67 13 mediastinal mediastinal ADJ dti-1422 67 14 tumor tumor NOUN dti-1422 67 15 during during ADP dti-1422 67 16 the the DET dti-1422 67 17 study study NOUN dti-1422 67 18 period period NOUN dti-1422 67 19 . . PUNCT dti-1422 68 1 one one NUM dti-1422 68 2 patient patient NOUN dti-1422 68 3 was be AUX dti-1422 68 4 lost lose VERB dti-1422 68 5 to to PART dti-1422 68 6 follow follow VERB dti-1422 68 7 - - PUNCT dti-1422 68 8 up up NOUN dti-1422 68 9 . . PUNCT dti-1422 69 1 three three NUM dti-1422 69 2 patients patient NOUN dti-1422 69 3 were be AUX dti-1422 69 4 removed remove VERB dti-1422 69 5 from from ADP dti-1422 69 6 the the DET dti-1422 69 7 analysis analysis NOUN dti-1422 69 8 because because SCONJ dti-1422 69 9 they they PRON dti-1422 69 10 were be AUX dti-1422 69 11 changed change VERB dti-1422 69 12 to to ADP dti-1422 69 13 different different ADJ dti-1422 69 14 prescription prescription NOUN dti-1422 69 15 drugs drug NOUN dti-1422 69 16 during during ADP dti-1422 69 17 the the DET dti-1422 69 18 study study NOUN dti-1422 69 19 period period NOUN dti-1422 69 20 . . PUNCT dti-1422 70 1 twenty twenty NUM dti-1422 70 2 patients patient NOUN dti-1422 70 3 completed complete VERB dti-1422 70 4 the the DET dti-1422 70 5 study study NOUN dti-1422 70 6 ( ( PUNCT dti-1422 70 7 fig fig NOUN dti-1422 70 8 . . PUNCT dti-1422 71 1 2 2 NUM dti-1422 71 2 ) ) PUNCT dti-1422 71 3 . . PUNCT dti-1422 72 1 the the DET dti-1422 72 2 baseline baseline PROPN dti-1422 72 3 characteristics characteristic NOUN dti-1422 72 4 of of ADP dti-1422 72 5 the the DET dti-1422 72 6 analyzed analyze VERB dti-1422 72 7 patients patient NOUN dti-1422 72 8 who who PRON dti-1422 72 9 completed complete VERB dti-1422 72 10 the the DET dti-1422 72 11 study study NOUN dti-1422 72 12 are be AUX dti-1422 72 13 listed list VERB dti-1422 72 14 in in ADP dti-1422 72 15 table table NOUN dti-1422 72 16 1 1 NUM dti-1422 72 17 . . PUNCT dti-1422 73 1 effects effect NOUN dti-1422 73 2 of of ADP dti-1422 73 3 linagliptin linagliptin NOUN dti-1422 73 4 on on ADP dti-1422 73 5 glucose glucose NOUN dti-1422 73 6 metabolism metabolism NOUN dti-1422 73 7 . . PUNCT dti-1422 74 1 linagliptin linagliptin PROPN dti-1422 74 2 significantly significantly ADV dti-1422 74 3 decreased decrease VERB dti-1422 74 4 hba1c hba1c PROPN dti-1422 74 5 levels level NOUN dti-1422 74 6 , , PUNCT dti-1422 74 7 but but CCONJ dti-1422 74 8 did do AUX dti-1422 74 9 not not PART dti-1422 74 10 change change VERB dti-1422 74 11 fasting fast VERB dti-1422 74 12 blood blood NOUN dti-1422 74 13 glucose glucose NOUN dti-1422 74 14 levels level NOUN dti-1422 74 15 ( ( PUNCT dti-1422 74 16 fig fig NOUN dti-1422 74 17 . . NOUN dti-1422 74 18 3 3 NUM dti-1422 74 19 and and CCONJ dti-1422 74 20 table table NOUN dti-1422 74 21 2 2 NUM dti-1422 74 22 ) ) PUNCT dti-1422 74 23 . . PUNCT dti-1422 75 1 effects effect NOUN dti-1422 75 2 of of ADP dti-1422 75 3 linagliptin linagliptin NOUN dti-1422 75 4 on on ADP dti-1422 75 5 lipid lipid ADJ dti-1422 75 6 metabolism metabolism NOUN dti-1422 75 7 and and CCONJ dti-1422 75 8 renal renal ADJ dti-1422 75 9 function function NOUN dti-1422 75 10 . . PUNCT dti-1422 76 1 linagliptin linagliptin PROPN dti-1422 76 2 significantly significantly ADV dti-1422 76 3 decreased decrease VERB dti-1422 76 4 total total ADJ dti-1422 76 5 cholesterol cholesterol NOUN dti-1422 76 6 and and CCONJ dti-1422 76 7 ldl ldl NOUN dti-1422 76 8 - - PUNCT dti-1422 76 9 cholesterol cholesterol NOUN dti-1422 76 10 levels level NOUN dti-1422 76 11 ( ( PUNCT dti-1422 76 12 fig fig NOUN dti-1422 76 13 . . NOUN dti-1422 76 14 4 4 NUM dti-1422 76 15 and and CCONJ dti-1422 76 16 table table NOUN dti-1422 76 17 2 2 NUM dti-1422 76 18 ) ) PUNCT dti-1422 76 19 , , PUNCT dti-1422 76 20 but but CCONJ dti-1422 76 21 did do AUX dti-1422 76 22 not not PART dti-1422 76 23 change change VERB dti-1422 76 24 hdl hdl NOUN dti-1422 76 25 - - PUNCT dti-1422 76 26 cholesterol cholesterol NOUN dti-1422 76 27 and and CCONJ dti-1422 76 28 triglyceride triglyceride ADJ dti-1422 76 29 levels level NOUN dti-1422 76 30 ( ( PUNCT dti-1422 76 31 fig fig NOUN dti-1422 76 32 . . NOUN dti-1422 76 33 4 4 NUM dti-1422 76 34 and and CCONJ dti-1422 76 35 table table NOUN dti-1422 76 36 2 2 NUM dti-1422 76 37 ) ) PUNCT dti-1422 76 38 ; ; PUNCT dti-1422 76 39 nor nor CCONJ dti-1422 76 40 did do AUX dti-1422 76 41 it it PRON dti-1422 76 42 change change VERB dti-1422 76 43 uacr uacr ADV dti-1422 76 44 and and CCONJ dti-1422 76 45 annual annual ADJ dti-1422 76 46 egfr egfr NOUN dti-1422 76 47 ( ( PUNCT dti-1422 76 48 fig fig NOUN dti-1422 76 49 . . NOUN dti-1422 76 50 5 5 NUM dti-1422 76 51 and and CCONJ dti-1422 76 52 table table NOUN dti-1422 76 53 2 2 NUM dti-1422 76 54 ) ) PUNCT dti-1422 76 55 . . PUNCT dti-1422 77 1 changes change NOUN dti-1422 77 2 in in ADP dti-1422 77 3 other other ADJ dti-1422 77 4 clinical clinical ADJ dti-1422 77 5 parameters parameter NOUN dti-1422 77 6 and and CCONJ dti-1422 77 7 adverse adverse ADJ dti-1422 77 8 effects effect NOUN dti-1422 77 9 . . PUNCT dti-1422 78 1 other other ADJ dti-1422 78 2 clinical clinical ADJ dti-1422 78 3 and and CCONJ dti-1422 78 4 laboratory laboratory NOUN dti-1422 78 5 parameters parameter NOUN dti-1422 78 6 were be AUX dti-1422 78 7 not not PART dti-1422 78 8 changed change VERB dti-1422 78 9 by by ADP dti-1422 78 10 the the DET dti-1422 78 11 administration administration NOUN dti-1422 78 12 of of ADP dti-1422 78 13 linagliptin linagliptin ADJ dti-1422 78 14 ( ( PUNCT dti-1422 78 15 table table NOUN dti-1422 78 16 2 2 NUM dti-1422 78 17 ) ) PUNCT dti-1422 78 18 . . PUNCT dti-1422 79 1 no no DET dti-1422 79 2 adverse adverse ADJ dti-1422 79 3 effects effect NOUN dti-1422 79 4 , , PUNCT dti-1422 79 5 including include VERB dti-1422 79 6 joint joint ADJ dti-1422 79 7 pain pain NOUN dti-1422 79 8 , , PUNCT dti-1422 79 9 hypoglycemia hypoglycemia NOUN dti-1422 79 10 , , PUNCT dti-1422 79 11 severe severe ADJ dti-1422 79 12 hyperglycemia hyperglycemia NOUN dti-1422 79 13 , , PUNCT dti-1422 79 14 ketosis ketosis NOUN dti-1422 79 15 , , PUNCT dti-1422 79 16 or or CCONJ dti-1422 79 17 electrolyte electrolyte NOUN dti-1422 79 18 abnormalities abnormality NOUN dti-1422 79 19 , , PUNCT dti-1422 79 20 were be AUX dti-1422 79 21 observed observe VERB dti-1422 79 22 in in ADP dti-1422 79 23 patients patient NOUN dti-1422 79 24 administered administer VERB dti-1422 79 25 linagliptin linagliptin NOUN dti-1422 79 26 during during ADP dti-1422 79 27 the the DET dti-1422 79 28 study study NOUN dti-1422 79 29 period period NOUN dti-1422 79 30 . . PUNCT dti-1422 80 1 discussion discussion NOUN dti-1422 80 2 in in ADP dti-1422 80 3 this this DET dti-1422 80 4 study study NOUN dti-1422 80 5 , , PUNCT dti-1422 80 6 linagliptin linagliptin ADJ dti-1422 80 7 as as ADP dti-1422 80 8 an an DET dti-1422 80 9 add add VERB dti-1422 80 10 - - PUNCT dti-1422 80 11 on on ADP dti-1422 80 12 therapy therapy NOUN dti-1422 80 13 significantly significantly ADV dti-1422 80 14 decreased decrease VERB dti-1422 80 15 hba1c hba1c PROPN dti-1422 80 16 and and CCONJ dti-1422 80 17 total total ADJ dti-1422 80 18 cholesterol cholesterol NOUN dti-1422 80 19 levels level NOUN dti-1422 80 20 in in ADP dti-1422 80 21 advancedstage advancedstage NOUN dti-1422 80 22 dmn dmn NOUN dti-1422 80 23 patients patient NOUN dti-1422 80 24 taking take VERB dti-1422 80 25 raas raas NOUN dti-1422 80 26 blockers blocker NOUN dti-1422 80 27 . . PUNCT dti-1422 81 1 linagliptin linagliptin PROPN dti-1422 81 2 administration administration PROPN dti-1422 81 3 did do AUX dti-1422 81 4 not not PART dti-1422 81 5 change change VERB dti-1422 81 6 uacr uacr ADV dti-1422 81 7 and and CCONJ dti-1422 81 8 annual annual ADJ dti-1422 81 9 egfr egfr NOUN dti-1422 81 10 , , PUNCT dti-1422 81 11 nor nor CCONJ dti-1422 81 12 did do AUX dti-1422 81 13 it it PRON dti-1422 81 14 show show VERB dti-1422 81 15 any any DET dti-1422 81 16 adverse adverse ADJ dti-1422 81 17 effects effect NOUN dti-1422 81 18 in in ADP dti-1422 81 19 the the DET dti-1422 81 20 patients patient NOUN dti-1422 81 21 . . PUNCT dti-1422 82 1 the the DET dti-1422 82 2 results result NOUN dti-1422 82 3 suggest suggest VERB dti-1422 82 4 that that SCONJ dti-1422 82 5 linagliptin linagliptin PROPN dti-1422 82 6 has have VERB dti-1422 82 7 beneficial beneficial ADJ dti-1422 82 8 effects effect NOUN dti-1422 82 9 on on ADP dti-1422 82 10 glucose glucose NOUN dti-1422 82 11 and and CCONJ dti-1422 82 12 lipid lipid NOUN dti-1422 82 13 metabolism metabolism NOUN dti-1422 82 14 and and CCONJ dti-1422 82 15 can can AUX dti-1422 82 16 be be AUX dti-1422 82 17 used use VERB dti-1422 82 18 safely safely ADV dti-1422 82 19 in in ADP dti-1422 82 20 such such ADJ dti-1422 82 21 populations population NOUN dti-1422 82 22 . . PUNCT dti-1422 83 1 linagliptin linagliptin PROPN dti-1422 83 2 did do AUX dti-1422 83 3 not not PART dti-1422 83 4 decrease decrease VERB dti-1422 83 5 fasting fast VERB dti-1422 83 6 blood blood NOUN dti-1422 83 7 glucose glucose NOUN dti-1422 83 8 levels level NOUN dti-1422 83 9 . . PUNCT dti-1422 84 1 it it PRON dti-1422 84 2 has have AUX dti-1422 84 3 been be AUX dti-1422 84 4 reported report VERB dti-1422 84 5 that that SCONJ dti-1422 84 6 linagliptin linagliptin ADJ dti-1422 84 7 decreases decrease NOUN dti-1422 84 8 postprandial postprandial ADJ dti-1422 84 9 glucose glucose NOUN dti-1422 84 10 levels level NOUN dti-1422 84 11 rather rather ADV dti-1422 84 12 than than ADP dti-1422 84 13 fasting fast VERB dti-1422 84 14 blood blood NOUN dti-1422 84 15 glucose glucose NOUN dti-1422 84 16 levels level NOUN dti-1422 84 17 because because SCONJ dti-1422 84 18 glp-1 glp-1 VERB dti-1422 84 19 , , PUNCT dti-1422 84 20 increased increase VERB dti-1422 84 21 by by ADP dti-1422 84 22 linagliptin linagliptin ADJ dti-1422 84 23 , , PUNCT dti-1422 84 24 is be AUX dti-1422 84 25 secreted secrete VERB dti-1422 84 26 from from ADP dti-1422 84 27 the the DET dti-1422 84 28 small small ADJ dti-1422 84 29 intestine intestine NOUN dti-1422 84 30 by by ADP dti-1422 84 31 the the DET dti-1422 84 32 stimulation stimulation NOUN dti-1422 84 33 of of ADP dti-1422 84 34 food.26 food.26 NOUN dti-1422 84 35 these these DET dti-1422 84 36 blood blood NOUN dti-1422 84 37 glucose glucose NOUN dti-1422 84 38 lowering lower VERB dti-1422 84 39 mechanisms mechanism NOUN dti-1422 84 40 of of ADP dti-1422 84 41 linagliptin linagliptin NOUN dti-1422 84 42 may may AUX dti-1422 84 43 explain explain VERB dti-1422 84 44 the the DET dti-1422 84 45 finding finding NOUN dti-1422 84 46 in in ADP dti-1422 84 47 the the DET dti-1422 84 48 current current ADJ dti-1422 84 49 study study NOUN dti-1422 84 50 that that PRON dti-1422 84 51 linagliptin linagliptin PROPN dti-1422 84 52 decreased decrease VERB dti-1422 84 53 hba1c hba1c PROPN dti-1422 84 54 levels level NOUN dti-1422 84 55 but but CCONJ dti-1422 84 56 did do AUX dti-1422 84 57 not not PART dti-1422 84 58 decrease decrease VERB dti-1422 84 59 fasting fast VERB dti-1422 84 60 blood blood NOUN dti-1422 84 61 glucose glucose NOUN dti-1422 84 62 levels level NOUN dti-1422 84 63 in in ADP dti-1422 84 64 dmn dmn PROPN dti-1422 84 65 patients patient NOUN dti-1422 84 66 . . PUNCT dti-1422 85 1 in in ADP dti-1422 85 2 addition addition NOUN dti-1422 85 3 to to ADP dti-1422 85 4 the the DET dti-1422 85 5 beneficial beneficial ADJ dti-1422 85 6 effects effect NOUN dti-1422 85 7 of of ADP dti-1422 85 8 linagliptin linagliptin NOUN dti-1422 85 9 on on ADP dti-1422 85 10 glucose glucose NOUN dti-1422 85 11 metabolism metabolism NOUN dti-1422 85 12 , , PUNCT dti-1422 85 13 beneficial beneficial ADJ dti-1422 85 14 effects effect NOUN dti-1422 85 15 have have AUX dti-1422 85 16 also also ADV dti-1422 85 17 been be AUX dti-1422 85 18 reported report VERB dti-1422 85 19 on on ADP dti-1422 85 20 lipid lipid ADJ dti-1422 85 21 metabolism metabolism NOUN dti-1422 85 22 as as ADV dti-1422 85 23 well well ADV dti-1422 85 24 as as ADP dti-1422 85 25 nephroprotective nephroprotective ADJ dti-1422 85 26 effects.22–24 effects.22–24 PRON dti-1422 85 27 although although SCONJ dti-1422 85 28 the the DET dti-1422 85 29 detailed detailed ADJ dti-1422 85 30 mechanisms mechanism NOUN dti-1422 85 31 have have AUX dti-1422 85 32 not not PART dti-1422 85 33 been be AUX dti-1422 85 34 fully fully ADV dti-1422 85 35 determined determine VERB dti-1422 85 36 , , PUNCT dti-1422 85 37 linagliptin linagliptin PROPN dti-1422 85 38 may may AUX dti-1422 85 39 improve improve VERB dti-1422 85 40 lipid lipid ADJ dti-1422 85 41 metabolism metabolism NOUN dti-1422 85 42 and and CCONJ dti-1422 85 43 show show VERB dti-1422 85 44 nephroprotective nephroprotective ADJ dti-1422 85 45 effects effect NOUN dti-1422 85 46 by by ADP dti-1422 85 47 improving improve VERB dti-1422 85 48 endothelial endothelial ADJ dti-1422 85 49 functions function NOUN dti-1422 85 50 and and CCONJ dti-1422 85 51 reducing reduce VERB dti-1422 85 52 pro pro ADJ dti-1422 85 53 - - ADJ dti-1422 85 54 oxidative oxidative ADJ dti-1422 85 55 and and CCONJ dti-1422 85 56 pro pro ADJ dti-1422 85 57 - - ADJ dti-1422 85 58 inflammatory inflammatory ADJ dti-1422 85 59 signals signal NOUN dti-1422 85 60 and and CCONJ dti-1422 85 61 inappropriate inappropriate ADJ dti-1422 85 62 sympathetic sympathetic ADJ dti-1422 85 63 nervous nervous ADJ dti-1422 85 64 system system NOUN dti-1422 85 65 activation activation NOUN dti-1422 85 66 through through ADP dti-1422 85 67 increasing increase VERB dti-1422 85 68 levels level NOUN dti-1422 85 69 of of ADP dti-1422 85 70 glp-1 glp-1 NOUN dti-1422 85 71 and and CCONJ dti-1422 85 72 other other ADJ dti-1422 85 73 ligands.26 ligands.26 ADJ dti-1422 85 74 previous previous ADJ dti-1422 85 75 large large ADJ dti-1422 85 76 - - PUNCT dti-1422 85 77 scale scale NOUN dti-1422 85 78 , , PUNCT dti-1422 85 79 double double ADJ dti-1422 85 80 - - PUNCT dti-1422 85 81 blind blind ADJ dti-1422 85 82 clinical clinical ADJ dti-1422 85 83 studies study NOUN dti-1422 85 84 have have AUX dti-1422 85 85 reported report VERB dti-1422 85 86 that that SCONJ dti-1422 85 87 linagliptin linagliptin ADJ dti-1422 85 88 improved improved ADJ dti-1422 85 89 glucose glucose NOUN dti-1422 85 90 metabolism metabolism NOUN dti-1422 85 91 in in ADP dti-1422 85 92 dmn dmn PROPN dti-1422 85 93 patients patient NOUN dti-1422 85 94 with with ADP dti-1422 85 95 renal renal ADJ dti-1422 85 96 impairment;21,22 impairment;21,22 NOUN dti-1422 85 97 however however ADV dti-1422 85 98 , , PUNCT dti-1422 85 99 the the DET dti-1422 85 100 effects effect NOUN dti-1422 85 101 of of ADP dti-1422 85 102 linagliptin linagliptin NOUN dti-1422 85 103 on on ADP dti-1422 85 104 lipid lipid ADJ dti-1422 85 105 metabolism metabolism NOUN dti-1422 85 106 in in ADP dti-1422 85 107 this this DET dti-1422 85 108 population population NOUN dti-1422 85 109 were be AUX dti-1422 85 110 not not PART dti-1422 85 111 studied study VERB dti-1422 85 112 . . PUNCT dti-1422 86 1 in in ADP dti-1422 86 2 the the DET dti-1422 86 3 current current ADJ dti-1422 86 4 study study NOUN dti-1422 86 5 , , PUNCT dti-1422 86 6 linagliptin linagliptin PROPN dti-1422 86 7 decreased decrease VERB dti-1422 86 8 total total ADJ dti-1422 86 9 cholesterol cholesterol NOUN dti-1422 86 10 and and CCONJ dti-1422 86 11 ldl ldl NOUN dti-1422 86 12 - - PUNCT dti-1422 86 13 cholesterol cholesterol NOUN dti-1422 86 14 levels level NOUN dti-1422 86 15 in in ADP dti-1422 86 16 addition addition NOUN dti-1422 86 17 to to ADP dti-1422 86 18 improving improve VERB dti-1422 86 19 glucose glucose NOUN dti-1422 86 20 metabolism metabolism NOUN dti-1422 86 21 in in ADP dti-1422 86 22 advanced advanced ADJ dti-1422 86 23 - - PUNCT dti-1422 86 24 stage stage NOUN dti-1422 86 25 dmn dmn NOUN dti-1422 86 26 patients patient NOUN dti-1422 86 27 taking take VERB dti-1422 86 28 raas raas NOUN dti-1422 86 29 blockers blocker NOUN dti-1422 86 30 . . PUNCT dti-1422 87 1 these these DET dti-1422 87 2 results result NOUN dti-1422 87 3 suggest suggest VERB dti-1422 87 4 that that SCONJ dti-1422 87 5 linagliptin linagliptin PROPN dti-1422 87 6 has have VERB dti-1422 87 7 beneficial beneficial ADJ dti-1422 87 8 effects effect NOUN dti-1422 87 9 on on ADP dti-1422 87 10 both both DET dti-1422 87 11 lipid lipid ADJ dti-1422 87 12 metabolism metabolism NOUN dti-1422 87 13 and and CCONJ dti-1422 87 14 glucose glucose NOUN dti-1422 87 15 metabolism metabolism NOUN dti-1422 87 16 in in ADP dti-1422 87 17 advanced advanced ADJ dti-1422 87 18 - - PUNCT dti-1422 87 19 stage stage NOUN dti-1422 87 20 dmn dmn NOUN dti-1422 87 21 patients patient NOUN dti-1422 87 22 . . PUNCT dti-1422 88 1 it it PRON dti-1422 88 2 should should AUX dti-1422 88 3 be be AUX dti-1422 88 4 noted note VERB dti-1422 88 5 that that SCONJ dti-1422 88 6 potential potential ADJ dti-1422 88 7 drug drug NOUN dti-1422 88 8 – – PUNCT dti-1422 88 9 drug drug NOUN dti-1422 88 10 interactions interaction NOUN dti-1422 88 11 might might AUX dti-1422 88 12 have have VERB dti-1422 88 13 an an DET dti-1422 88 14 effect effect NOUN dti-1422 88 15 on on ADP dti-1422 88 16 the the DET dti-1422 88 17 results result NOUN dti-1422 88 18 of of ADP dti-1422 88 19 the the DET dti-1422 88 20 current current ADJ dti-1422 88 21 study study NOUN dti-1422 88 22 because because SCONJ dti-1422 88 23 the the DET dti-1422 88 24 enrolled enrol VERB dti-1422 88 25 patients patient NOUN dti-1422 88 26 were be AUX dti-1422 88 27 on on ADP dti-1422 88 28 different different ADJ dti-1422 88 29 types type NOUN dti-1422 88 30 of of ADP dti-1422 88 31 drugs drug NOUN dti-1422 88 32 to to PART dti-1422 88 33 control control VERB dti-1422 88 34 hyperglycemia hyperglycemia NOUN dti-1422 88 35 and and CCONJ dti-1422 88 36 hyperlipidemia hyperlipidemia NOUN dti-1422 88 37 . . PUNCT dti-1422 89 1 further further ADJ dti-1422 89 2 studies study NOUN dti-1422 89 3 are be AUX dti-1422 89 4 required require VERB dti-1422 89 5 to to PART dti-1422 89 6 elucidate elucidate VERB dti-1422 89 7 the the DET dti-1422 89 8 figure figure NOUN dti-1422 89 9 2 2 NUM dti-1422 89 10 . . PUNCT dti-1422 89 11 patient patient PROPN dti-1422 89 12 flowchart flowchart PROPN dti-1422 89 13 . . PUNCT dti-1422 90 1 table table NOUN dti-1422 90 2 1 1 NUM dti-1422 90 3 . . PUNCT dti-1422 91 1 patients patient NOUN dti-1422 91 2 ’ ' PUNCT dti-1422 91 3 baseline baseline VERB dti-1422 91 4 characteristic characteristic ADJ dti-1422 91 5 . . PUNCT dti-1422 92 1 number number NOUN dti-1422 92 2 20 20 NUM dti-1422 92 3 age age NOUN dti-1422 92 4 ( ( PUNCT dti-1422 92 5 years year NOUN dti-1422 92 6 ) ) PUNCT dti-1422 92 7 69.7 69.7 NUM dti-1422 92 8 ± ± NUM dti-1422 92 9 12.9 12.9 NUM dti-1422 92 10 gender gender NOUN dti-1422 92 11 ( ( PUNCT dti-1422 92 12 male male NOUN dti-1422 92 13 / / SYM dti-1422 92 14 female female NOUN dti-1422 92 15 ) ) PUNCT dti-1422 92 16 14/6 14/6 NUM dti-1422 92 17 ckd ckd NOUN dti-1422 92 18 stage stage NOUN dti-1422 92 19 ( ( PUNCT dti-1422 92 20 number number NOUN dti-1422 92 21 ) ) PUNCT dti-1422 92 22 stage stage NOUN dti-1422 92 23 3 3 NUM dti-1422 92 24 5 5 NUM dti-1422 92 25 stage stage NOUN dti-1422 92 26 4 4 NUM dti-1422 92 27 9 9 NUM dti-1422 92 28 stage stage NOUN dti-1422 92 29 5 5 NUM dti-1422 92 30 6 6 NUM dti-1422 92 31 raas raas NOUN dti-1422 92 32 blockers blocker NOUN dti-1422 92 33 ace ace VERB dti-1422 92 34 5 5 NUM dti-1422 92 35 arb arb NOUN dti-1422 92 36 20 20 NUM dti-1422 92 37 anti anti ADJ dti-1422 92 38 - - ADJ dti-1422 92 39 hyperglycemic hyperglycemic ADJ dti-1422 92 40 drugs drug NOUN dti-1422 92 41 biguanide biguanide VERB dti-1422 92 42 3 3 NUM dti-1422 92 43 glinides glinide NOUN dti-1422 92 44 2 2 NUM dti-1422 92 45 sulfonylurea sulfonylurea NOUN dti-1422 92 46 1 1 NUM dti-1422 92 47 α α NOUN dti-1422 92 48 - - PUNCT dti-1422 92 49 glucosidase glucosidase ADJ dti-1422 92 50 inhibitors inhibitor NOUN dti-1422 92 51 6 6 NUM dti-1422 92 52 thiazolidinedione thiazolidinedione NUM dti-1422 92 53 4 4 NUM dti-1422 92 54 insulin insulin NOUN dti-1422 92 55 agents agent NOUN dti-1422 92 56 10 10 NUM dti-1422 92 57 hypolipidemic hypolipidemic ADJ dti-1422 92 58 drugs drug NOUN dti-1422 92 59 statins statin VERB dti-1422 92 60 11 11 NUM dti-1422 92 61 ezetimibe ezetimibe NOUN dti-1422 92 62 1 1 NUM dti-1422 92 63 fenofibrate fenofibrate NOUN dti-1422 92 64 1 1 NUM dti-1422 92 65 abbreviations abbreviation NOUN dti-1422 92 66 : : PUNCT dti-1422 92 67 ckd ckd NOUN dti-1422 92 68 , , PUNCT dti-1422 92 69 chronic chronic ADJ dti-1422 92 70 kidney kidney NOUN dti-1422 92 71 disease disease NOUN dti-1422 92 72 ; ; PUNCT dti-1422 92 73 raas raas NOUN dti-1422 92 74 blockers blocker NOUN dti-1422 92 75 , , PUNCT dti-1422 92 76 renin renin ADJ dti-1422 92 77 – – PUNCT dti-1422 92 78 angiotensin angiotensin NOUN dti-1422 92 79 – – PUNCT dti-1422 92 80 aldosterone aldosterone NOUN dti-1422 92 81 system system NOUN dti-1422 92 82 blockers blocker NOUN dti-1422 92 83 ; ; PUNCT dti-1422 92 84 ace ace NOUN dti-1422 92 85 , , PUNCT dti-1422 92 86 angiotensin angiotensin NOUN dti-1422 92 87 - - PUNCT dti-1422 92 88 converting convert VERB dti-1422 92 89 enzyme enzyme NOUN dti-1422 92 90 inhibitors inhibitor NOUN dti-1422 92 91 ; ; PUNCT dti-1422 92 92 arb arb PROPN dti-1422 92 93 , , PUNCT dti-1422 92 94 angiotensin angiotensin NOUN dti-1422 92 95 ii ii NOUN dti-1422 92 96 - - PUNCT dti-1422 92 97 receptor receptor NOUN dti-1422 92 98 blockers blocker NOUN dti-1422 92 99 . . PUNCT dti-1422 93 1 http://www.la-press.com http://www.la-press.com X dti-1422 93 2 http://www.la-press.com/drug-target-insights-journal-j23 http://www.la-press.com/drug-target-insights-journal-j23 AUX dti-1422 93 3 ueda ueda PROPN dti-1422 93 4 et et PROPN dti-1422 93 5 al al PROPN dti-1422 93 6 16 16 NUM dti-1422 93 7 drug drug NOUN dti-1422 93 8 target target NOUN dti-1422 93 9 insights insight NOUN dti-1422 93 10 2016:10 2016:10 NUM dti-1422 93 11 mechanisms mechanism NOUN dti-1422 93 12 behind behind ADP dti-1422 93 13 the the DET dti-1422 93 14 effects effect NOUN dti-1422 93 15 of of ADP dti-1422 93 16 linagliptin linagliptin NOUN dti-1422 93 17 on on ADP dti-1422 93 18 glucose glucose NOUN dti-1422 93 19 and and CCONJ dti-1422 93 20 lipid lipid NOUN dti-1422 93 21 metabolism metabolism NOUN dti-1422 93 22 and and CCONJ dti-1422 93 23 its its PRON dti-1422 93 24 interactions interaction NOUN dti-1422 93 25 with with ADP dti-1422 93 26 other other ADJ dti-1422 93 27 drugs drug NOUN dti-1422 93 28 . . PUNCT dti-1422 94 1 it it PRON dti-1422 94 2 has have AUX dti-1422 94 3 been be AUX dti-1422 94 4 reported report VERB dti-1422 94 5 that that SCONJ dti-1422 94 6 linagliptin linagliptin PROPN dti-1422 94 7 decreased decrease VERB dti-1422 94 8 uacr uacr ADV dti-1422 94 9 in in ADP dti-1422 94 10 the the DET dti-1422 94 11 early early ADJ dti-1422 94 12 to to PART dti-1422 94 13 middle middle ADJ dti-1422 94 14 stages stage NOUN dti-1422 94 15 of of ADP dti-1422 94 16 dmn dmn PROPN dti-1422 94 17 patients patient NOUN dti-1422 94 18 over over ADP dti-1422 94 19 the the DET dti-1422 94 20 course course NOUN dti-1422 94 21 of of ADP dti-1422 94 22 a a DET dti-1422 94 23 24 24 NUM dti-1422 94 24 - - PUNCT dti-1422 94 25 week week NOUN dti-1422 94 26 study study NOUN dti-1422 94 27 period.22 period.22 NOUN dti-1422 94 28 another another DET dti-1422 94 29 study study NOUN dti-1422 94 30 reported report VERB dti-1422 94 31 that that SCONJ dti-1422 94 32 linagliptin linagliptin PROPN dti-1422 94 33 had have VERB dti-1422 94 34 little little ADJ dti-1422 94 35 effect effect NOUN dti-1422 94 36 on on ADP dti-1422 94 37 renal renal ADJ dti-1422 94 38 function function NOUN dti-1422 94 39 in in ADP dti-1422 94 40 dmn dmn PROPN dti-1422 94 41 patients patient NOUN dti-1422 94 42 with with ADP dti-1422 94 43 severe severe ADJ dti-1422 94 44 renal renal ADJ dti-1422 94 45 impairment impairment NOUN dti-1422 94 46 over over ADP dti-1422 94 47 a a DET dti-1422 94 48 1 1 NUM dti-1422 94 49 - - PUNCT dti-1422 94 50 year year NOUN dti-1422 94 51 study study NOUN dti-1422 94 52 period.21 period.21 NOUN dti-1422 94 53 in in ADP dti-1422 94 54 the the DET dti-1422 94 55 current current ADJ dti-1422 94 56 study study NOUN dti-1422 94 57 , , PUNCT dti-1422 94 58 the the DET dti-1422 94 59 nephroprotective nephroprotective ADJ dti-1422 94 60 effects effect NOUN dti-1422 94 61 of of ADP dti-1422 94 62 linagliptin linagliptin NOUN dti-1422 94 63 were be AUX dti-1422 94 64 not not PART dti-1422 94 65 observed observe VERB dti-1422 94 66 over over ADP dti-1422 94 67 52 52 NUM dti-1422 94 68     SPACE dti-1422 94 69 weeks week NOUN dti-1422 94 70 . . PUNCT dti-1422 95 1 these these DET dti-1422 95 2 results result NOUN dti-1422 95 3 suggest suggest VERB dti-1422 95 4 that that SCONJ dti-1422 95 5 linagliptin linagliptin NOUN dti-1422 95 6 does do AUX dti-1422 95 7 not not PART dti-1422 95 8 have have VERB dti-1422 95 9 nephroprotective nephroprotective ADJ dti-1422 95 10 effects effect NOUN dti-1422 95 11 on on ADP dti-1422 95 12 figure figure NOUN dti-1422 95 13 3 3 NUM dti-1422 95 14 . . PUNCT dti-1422 95 15 changes change NOUN dti-1422 95 16 in in ADP dti-1422 95 17 hba1c hba1c PROPN dti-1422 95 18 and and CCONJ dti-1422 95 19 fasting fast VERB dti-1422 95 20 blood blood NOUN dti-1422 95 21 glucose glucose NOUN dti-1422 95 22 ( ( PUNCT dti-1422 95 23 all all DET dti-1422 95 24 patients patient NOUN dti-1422 95 25 , , PUNCT dti-1422 95 26 n n NOUN dti-1422 95 27 = = NUM dti-1422 95 28 20 20 NUM dti-1422 95 29 ) ) PUNCT dti-1422 95 30 . . PUNCT dti-1422 96 1 note note VERB dti-1422 96 2 : : PUNCT dti-1422 97 1 * * PUNCT dti-1422 97 2 p p NOUN dti-1422 97 3 , , PUNCT dti-1422 97 4 0.05 0.05 NUM dti-1422 97 5 vs vs ADP dti-1422 97 6 baseline baseline NOUN dti-1422 97 7 . . PUNCT dti-1422 98 1 abbreviations abbreviation NOUN dti-1422 98 2 : : PUNCT dti-1422 98 3 hba1c hba1c NOUN dti-1422 98 4 , , PUNCT dti-1422 98 5 glycosylated glycosylated ADJ dti-1422 98 6 hemoglobin hemoglobin NOUN dti-1422 98 7 ; ; PUNCT dti-1422 98 8 ns ns X dti-1422 98 9 , , PUNCT dti-1422 98 10 not not PART dti-1422 98 11 significant significant ADJ dti-1422 98 12 . . PUNCT dti-1422 99 1 table table NOUN dti-1422 99 2 2 2 NUM dti-1422 99 3 . . PUNCT dti-1422 99 4 changes change NOUN dti-1422 99 5 in in ADP dti-1422 99 6 parameters parameter NOUN dti-1422 99 7 before before ADP dti-1422 99 8 and and CCONJ dti-1422 99 9 after after ADP dti-1422 99 10 linagliptin linagliptin PROPN dti-1422 99 11 administration administration PROPN dti-1422 99 12 . . PUNCT dti-1422 100 1 parameter parameter PROPN dti-1422 100 2 at at ADP dti-1422 100 3 baseline baseline NOUN dti-1422 100 4 at at ADP dti-1422 100 5 52 52 NUM dti-1422 100 6 weeks week NOUN dti-1422 100 7 after after ADP dti-1422 100 8 linagliptin linagliptin PROPN dti-1422 100 9 administration administration PROPN dti-1422 100 10 statistics statistics PROPN dti-1422 100 11 sbp sbp PROPN dti-1422 100 12 ( ( PUNCT dti-1422 100 13 mmhg mmhg PROPN dti-1422 100 14 ) ) PUNCT dti-1422 100 15 141.1 141.1 NUM dti-1422 100 16 ± ± NUM dti-1422 100 17 16.6 16.6 NUM dti-1422 100 18 144.4 144.4 NUM dti-1422 100 19 ± ± NUM dti-1422 100 20 19.8 19.8 NUM dti-1422 100 21 ns ns NUM dti-1422 100 22 dbp dbp PROPN dti-1422 100 23 ( ( PUNCT dti-1422 100 24 mmhg mmhg PROPN dti-1422 100 25 ) ) PUNCT dti-1422 100 26 72.5 72.5 NUM dti-1422 100 27 ± ± NUM dti-1422 100 28 11.8 11.8 NUM dti-1422 100 29 77.4 77.4 NUM dti-1422 100 30 ± ± NUM dti-1422 100 31 14.4 14.4 NUM dti-1422 100 32 ns ns NUM dti-1422 100 33 hr hr NOUN dti-1422 100 34 ( ( PUNCT dti-1422 100 35 beats beat NOUN dti-1422 100 36 / / SYM dti-1422 100 37 min min NOUN dti-1422 100 38 ) ) PUNCT dti-1422 100 39 78.1 78.1 NUM dti-1422 100 40 ± ± NUM dti-1422 100 41 12.6 12.6 NUM dti-1422 100 42 78.2 78.2 NUM dti-1422 100 43 ± ± NUM dti-1422 100 44 11.0 11.0 NUM dti-1422 100 45 ns ns NUM dti-1422 100 46 creatinine creatinine NOUN dti-1422 100 47 ( ( PUNCT dti-1422 100 48 mg mg PROPN dti-1422 100 49 / / SYM dti-1422 100 50 dl dl NOUN dti-1422 100 51 ) ) PUNCT dti-1422 100 52 2.5 2.5 NUM dti-1422 100 53 ± ± NUM dti-1422 100 54 1.0 1.0 NUM dti-1422 100 55 3.6 3.6 NUM dti-1422 100 56 ± ± NUM dti-1422 100 57 2.2 2.2 NUM dti-1422 100 58 * * NOUN dti-1422 100 59 egfr egfr X dti-1422 100 60 ( ( PUNCT dti-1422 100 61 ml ml NOUN dti-1422 100 62 / / SYM dti-1422 100 63 min/1.73 min/1.73 NOUN dti-1422 100 64 m2 m2 PROPN dti-1422 100 65 ) ) PUNCT dti-1422 100 66 24.5 24.5 NUM dti-1422 100 67 ± ± NUM dti-1422 100 68 13.2 13.2 NUM dti-1422 100 69 19.5 19.5 NUM dti-1422 100 70 ± ± NUM dti-1422 100 71 13.0 13.0 NUM dti-1422 100 72 * * PUNCT dti-1422 100 73 * * PUNCT dti-1422 100 74 annual annual ADJ dti-1422 100 75 egfr egfr NOUN dti-1422 100 76 change change NOUN dti-1422 100 77 ( ( PUNCT dti-1422 100 78 ml ml NOUN dti-1422 100 79 / / SYM dti-1422 100 80 min/1.73 min/1.73 NOUN dti-1422 100 81 m2 m2 PROPN dti-1422 100 82 / / SYM dti-1422 100 83 years year NOUN dti-1422 100 84 ) ) PUNCT dti-1422 100 85 -6.5 -6.5 X dti-1422 100 86 ± ± NUM dti-1422 100 87 14.2 14.2 NUM dti-1422 100 88 -4.0 -4.0 X dti-1422 100 89 ± ± NUM dti-1422 100 90 3.8 3.8 NUM dti-1422 100 91 ns ns NUM dti-1422 101 1 uacr uacr INTJ dti-1422 102 1 ( ( PUNCT dti-1422 102 2 g g NOUN dti-1422 102 3 / / SYM dti-1422 102 4 g g PROPN dti-1422 102 5 cr cr PROPN dti-1422 102 6 ) ) PUNCT dti-1422 102 7 2.2 2.2 NUM dti-1422 102 8 ± ± NUM dti-1422 102 9 2.6 2.6 NUM dti-1422 102 10 1.9 1.9 NUM dti-1422 102 11 ± ± NUM dti-1422 102 12 2.4 2.4 NUM dti-1422 102 13 ns ns NUM dti-1422 102 14 hba1c hba1c PROPN dti-1422 102 15 ( ( PUNCT dti-1422 102 16 % % NOUN dti-1422 102 17 ) ) PUNCT dti-1422 102 18 7.3 7.3 NUM dti-1422 102 19 ± ± NUM dti-1422 102 20 0.8 0.8 NUM dti-1422 102 21 6.9 6.9 NUM dti-1422 102 22 ± ± NUM dti-1422 102 23 0.8 0.8 NUM dti-1422 102 24 * * PUNCT dti-1422 102 25 blood blood NOUN dti-1422 102 26 glucose glucose NOUN dti-1422 102 27 ( ( PUNCT dti-1422 102 28 mg mg PROPN dti-1422 102 29 / / SYM dti-1422 102 30 dl dl NOUN dti-1422 102 31 ) ) PUNCT dti-1422 102 32 162.2 162.2 NUM dti-1422 102 33 ± ± NOUN dti-1422 102 34 54.9 54.9 NUM dti-1422 102 35 158.7 158.7 NUM dti-1422 102 36 ± ± NUM dti-1422 102 37 64.6 64.6 NUM dti-1422 102 38 ns ns NUM dti-1422 102 39 total total ADJ dti-1422 102 40 cholesterol cholesterol NOUN dti-1422 102 41 ( ( PUNCT dti-1422 102 42 mg mg PROPN dti-1422 102 43 / / SYM dti-1422 102 44 dl dl NOUN dti-1422 102 45 ) ) PUNCT dti-1422 102 46 189.6 189.6 NUM dti-1422 102 47 ± ± NOUN dti-1422 102 48 49.0 49.0 NUM dti-1422 102 49 168.47 168.47 NUM dti-1422 102 50 ± ± NUM dti-1422 102 51 38.7 38.7 NUM dti-1422 102 52 * * PUNCT dti-1422 102 53 ldl ldl NOUN dti-1422 102 54 - - PUNCT dti-1422 102 55 cholesterol cholesterol NOUN dti-1422 102 56 ( ( PUNCT dti-1422 102 57 mg mg PROPN dti-1422 102 58 / / SYM dti-1422 102 59 dl dl NOUN dti-1422 102 60 ) ) PUNCT dti-1422 102 61 107.1 107.1 NUM dti-1422 102 62 ± ± NUM dti-1422 102 63 32.4 32.4 NUM dti-1422 102 64 90.2 90.2 NUM dti-1422 102 65 ± ± NUM dti-1422 102 66 31.0 31.0 NUM dti-1422 102 67 * * PUNCT dti-1422 102 68 hdl hdl PROPN dti-1422 102 69 - - PUNCT dti-1422 102 70 cholesterol cholesterol NOUN dti-1422 102 71 ( ( PUNCT dti-1422 102 72 mg mg PROPN dti-1422 102 73 / / SYM dti-1422 102 74 dl dl NOUN dti-1422 102 75 ) ) PUNCT dti-1422 102 76 40.8 40.8 NUM dti-1422 102 77 ± ± NUM dti-1422 102 78 8.4 8.4 NUM dti-1422 102 79 43.6 43.6 NUM dti-1422 102 80 ± ± NUM dti-1422 102 81 12.1 12.1 NUM dti-1422 102 82 ns ns NUM dti-1422 102 83 triglyceride triglyceride INTJ dti-1422 102 84 ( ( PUNCT dti-1422 102 85 mg mg PROPN dti-1422 102 86 / / SYM dti-1422 102 87 dl dl NOUN dti-1422 102 88 ) ) PUNCT dti-1422 102 89 225.7 225.7 NUM dti-1422 102 90 ± ± NUM dti-1422 102 91 126.4 126.4 NUM dti-1422 102 92 208.4 208.4 NUM dti-1422 102 93 ± ± NUM dti-1422 102 94 108.0 108.0 NUM dti-1422 102 95 ns ns NUM dti-1422 102 96 total total ADJ dti-1422 102 97 protein protein NOUN dti-1422 102 98 ( ( PUNCT dti-1422 102 99 g g PROPN dti-1422 102 100 / / SYM dti-1422 102 101 dl dl NOUN dti-1422 102 102 ) ) PUNCT dti-1422 102 103 6.9 6.9 NUM dti-1422 102 104 ± ± NUM dti-1422 102 105 0.8 0.8 NUM dti-1422 102 106 6.8 6.8 NUM dti-1422 102 107 ± ± NUM dti-1422 102 108 0.5 0.5 NUM dti-1422 102 109 ns ns NUM dti-1422 102 110 albumin albumin NOUN dti-1422 102 111 ( ( PUNCT dti-1422 102 112 g g PROPN dti-1422 102 113 / / SYM dti-1422 102 114 dl dl NOUN dti-1422 102 115 ) ) PUNCT dti-1422 102 116 3.8 3.8 NUM dti-1422 102 117 ± ± NUM dti-1422 102 118 0.6 0.6 NUM dti-1422 102 119 3.7 3.7 NUM dti-1422 102 120 ± ± NUM dti-1422 102 121 0.5 0.5 NUM dti-1422 102 122 ns ns NUM dti-1422 102 123 sodium sodium NOUN dti-1422 102 124 ( ( PUNCT dti-1422 102 125 mmol mmol NOUN dti-1422 102 126 / / SYM dti-1422 102 127 l l NOUN dti-1422 102 128 ) ) PUNCT dti-1422 102 129 139.0 139.0 NUM dti-1422 102 130 ± ± NUM dti-1422 102 131 2.7 2.7 NUM dti-1422 102 132 139.5 139.5 NUM dti-1422 102 133 ± ± NUM dti-1422 102 134 2.9 2.9 NUM dti-1422 102 135 ns ns NUM dti-1422 102 136 potassium potassium NOUN dti-1422 102 137 ( ( PUNCT dti-1422 102 138 mmol mmol NOUN dti-1422 102 139 / / SYM dti-1422 102 140 l l NOUN dti-1422 102 141 ) ) PUNCT dti-1422 102 142 4.6 4.6 NUM dti-1422 102 143 ± ± NUM dti-1422 102 144 0.8 0.8 NUM dti-1422 102 145 4.6 4.6 NUM dti-1422 102 146 ± ± NUM dti-1422 102 147 0.6 0.6 NUM dti-1422 102 148 ns ns NUM dti-1422 102 149 chloride chloride NOUN dti-1422 102 150 ( ( PUNCT dti-1422 102 151 mmol mmol NOUN dti-1422 102 152 / / SYM dti-1422 102 153 l l NOUN dti-1422 102 154 ) ) PUNCT dti-1422 102 155 105.6 105.6 NUM dti-1422 102 156 ± ± NUM dti-1422 102 157 4.8 4.8 NUM dti-1422 102 158 107.6 107.6 NUM dti-1422 102 159 ± ± NUM dti-1422 102 160 3.8 3.8 NUM dti-1422 102 161 ns ns NUM dti-1422 102 162 calcium calcium NOUN dti-1422 102 163 ( ( PUNCT dti-1422 102 164 mg mg PROPN dti-1422 102 165 / / SYM dti-1422 102 166 dl dl NOUN dti-1422 102 167 ) ) PUNCT dti-1422 102 168 9.0 9.0 NUM dti-1422 102 169 ± ± NUM dti-1422 102 170 0.5 0.5 NUM dti-1422 102 171 8.5 8.5 NUM dti-1422 102 172 ± ± NUM dti-1422 102 173 0.8 0.8 NUM dti-1422 102 174 * * PUNCT dti-1422 102 175 phosphate phosphate ADJ dti-1422 102 176 ( ( PUNCT dti-1422 102 177 mg mg PROPN dti-1422 102 178 / / SYM dti-1422 102 179 dl dl NOUN dti-1422 102 180 ) ) PUNCT dti-1422 102 181 3.7 3.7 NUM dti-1422 102 182 ± ± NUM dti-1422 102 183 0.7 0.7 NUM dti-1422 102 184 4.3 4.3 NUM dti-1422 102 185 ± ± NUM dti-1422 102 186 1.3 1.3 NUM dti-1422 102 187 ns ns NUM dti-1422 102 188 notes note NOUN dti-1422 102 189 : : PUNCT dti-1422 102 190 * * PUNCT dti-1422 102 191 p p NOUN dti-1422 102 192 , , PUNCT dti-1422 102 193 0.05 0.05 NUM dti-1422 102 194 ; ; PUNCT dti-1422 102 195 * * PUNCT dti-1422 102 196 * * PUNCT dti-1422 102 197 p p X dti-1422 102 198 , , PUNCT dti-1422 102 199 0.01 0.01 NUM dti-1422 102 200 . . PUNCT dti-1422 103 1 abbreviations abbreviation NOUN dti-1422 103 2 : : PUNCT dti-1422 103 3 sbp sbp NOUN dti-1422 103 4 , , PUNCT dti-1422 103 5 systolic systolic ADJ dti-1422 103 6 blood blood NOUN dti-1422 103 7 pressure pressure NOUN dti-1422 103 8 ; ; PUNCT dti-1422 103 9 dbp dbp PROPN dti-1422 103 10 , , PUNCT dti-1422 103 11 diastolic diastolic ADJ dti-1422 103 12 blood blood NOUN dti-1422 103 13 pressure pressure NOUN dti-1422 103 14 ; ; PUNCT dti-1422 103 15 hr hr NOUN dti-1422 103 16 , , PUNCT dti-1422 103 17 heart heart NOUN dti-1422 103 18 rate rate NOUN dti-1422 103 19 ; ; PUNCT dti-1422 103 20 egfr egfr X dti-1422 103 21 , , PUNCT dti-1422 103 22 estimated estimate VERB dti-1422 103 23 glomerular glomerular ADJ dti-1422 103 24 filtration filtration NOUN dti-1422 103 25 rate rate NOUN dti-1422 103 26 ; ; PUNCT dti-1422 103 27 ckd ckd PROPN dti-1422 103 28 , , PUNCT dti-1422 103 29 chronic chronic ADJ dti-1422 103 30 kidney kidney NOUN dti-1422 103 31 disease disease NOUN dti-1422 103 32 ; ; PUNCT dti-1422 103 33 uacr uacr INTJ dti-1422 103 34 , , PUNCT dti-1422 103 35 urine urine ADJ dti-1422 103 36 protein protein NOUN dti-1422 103 37 / / SYM dti-1422 103 38 creatinine creatinine NOUN dti-1422 103 39 ratio ratio NOUN dti-1422 103 40 ; ; PUNCT dti-1422 103 41 hba1c hba1c PROPN dti-1422 103 42 , , PUNCT dti-1422 103 43 glycosylated glycosylated ADJ dti-1422 103 44 hemoglobin hemoglobin NOUN dti-1422 103 45 ; ; PUNCT dti-1422 103 46 ldl ldl NOUN dti-1422 103 47 , , PUNCT dti-1422 103 48 low low ADJ dti-1422 103 49 - - PUNCT dti-1422 103 50 density density NOUN dti-1422 103 51 lipoprotein lipoprotein NOUN dti-1422 103 52 ; ; PUNCT dti-1422 103 53 hdl hdl X dti-1422 103 54 , , PUNCT dti-1422 103 55 high high ADJ dti-1422 103 56 - - PUNCT dti-1422 103 57 density density NOUN dti-1422 103 58 lipoprotein lipoprotein NOUN dti-1422 103 59 ; ; PUNCT dti-1422 103 60 ns ns NUM dti-1422 103 61 , , PUNCT dti-1422 103 62 not not PART dti-1422 103 63 significant significant ADJ dti-1422 103 64 . . PUNCT dti-1422 104 1 http://www.la-press.com http://www.la-press.com X dti-1422 105 1 http://www.la-press.com/drug-target-insights-journal-j23 http://www.la-press.com/drug-target-insights-journal-j23 PROPN dti-1422 105 2 effects effect NOUN dti-1422 105 3 and and CCONJ dti-1422 105 4 safety safety NOUN dti-1422 105 5 of of ADP dti-1422 105 6 linagliptin linagliptin NOUN dti-1422 105 7 as as ADP dti-1422 105 8 an an DET dti-1422 105 9 add add VERB dti-1422 105 10 - - PUNCT dti-1422 105 11 on on ADP dti-1422 105 12 therapy therapy NOUN dti-1422 105 13 17drug 17drug PROPN dti-1422 105 14 target target PROPN dti-1422 105 15 insights insight NOUN dti-1422 105 16 2016:10 2016:10 NUM dti-1422 105 17 advanced advanced ADJ dti-1422 105 18 - - PUNCT dti-1422 105 19 stage stage NOUN dti-1422 105 20 dmn dmn NOUN dti-1422 105 21 patients patient NOUN dti-1422 105 22 over over ADP dti-1422 105 23 the the DET dti-1422 105 24 long long ADJ dti-1422 105 25 term term NOUN dti-1422 105 26 . . PUNCT dti-1422 106 1 linagliptin linagliptin PROPN dti-1422 106 2 may may AUX dti-1422 106 3 have have VERB dti-1422 106 4 nephroprotective nephroprotective ADJ dti-1422 106 5 effects effect NOUN dti-1422 106 6 at at ADP dti-1422 106 7 the the DET dti-1422 106 8 early early ADJ dti-1422 106 9 to to PART dti-1422 106 10 middle middle ADJ dti-1422 106 11 stages stage NOUN dti-1422 106 12 of of ADP dti-1422 106 13 dmn dmn NOUN dti-1422 106 14 , , PUNCT dti-1422 106 15 as as SCONJ dti-1422 106 16 previously previously ADV dti-1422 106 17 reported.22 reported.22 VERB dti-1422 106 18 large large ADJ dti-1422 106 19 - - PUNCT dti-1422 106 20 scale scale NOUN dti-1422 106 21 , , PUNCT dti-1422 106 22 long long ADJ dti-1422 106 23 - - PUNCT dti-1422 106 24 term term NOUN dti-1422 106 25 clinical clinical ADJ dti-1422 106 26 studies study NOUN dti-1422 106 27 investigating investigate VERB dti-1422 106 28 the the DET dti-1422 106 29 nephroprotective nephroprotective ADJ dti-1422 106 30 effects effect NOUN dti-1422 106 31 of of ADP dti-1422 106 32 linagliptin linagliptin NOUN dti-1422 106 33 at at ADP dti-1422 106 34 each each DET dti-1422 106 35 stage stage NOUN dti-1422 106 36 of of ADP dti-1422 106 37 dmn dmn PROPN dti-1422 106 38 are be AUX dti-1422 106 39 required require VERB dti-1422 106 40 . . PUNCT dti-1422 107 1 linagliptin linagliptin PROPN dti-1422 107 2 did do AUX dti-1422 107 3 not not PART dti-1422 107 4 induce induce VERB dti-1422 107 5 any any DET dti-1422 107 6 adverse adverse ADJ dti-1422 107 7 effects effect NOUN dti-1422 107 8 , , PUNCT dti-1422 107 9 including include VERB dti-1422 107 10 joint joint ADJ dti-1422 107 11 pain pain NOUN dti-1422 107 12 , , PUNCT dti-1422 107 13 blood blood NOUN dti-1422 107 14 pressure pressure NOUN dti-1422 107 15 , , PUNCT dti-1422 107 16 and and CCONJ dti-1422 107 17 electrolyte electrolyte ADJ dti-1422 107 18 abnormalities abnormality NOUN dti-1422 107 19 , , PUNCT dti-1422 107 20 in in ADP dti-1422 107 21 the the DET dti-1422 107 22 current current ADJ dti-1422 107 23 study study NOUN dti-1422 107 24 ’s ’s PART dti-1422 107 25 population population NOUN dti-1422 107 26 , , PUNCT dti-1422 107 27 which which PRON dti-1422 107 28 suggests suggest VERB dti-1422 107 29 that that SCONJ dti-1422 107 30 linagliptin linagliptin PROPN dti-1422 107 31 can can AUX dti-1422 107 32 be be AUX dti-1422 107 33 used use VERB dti-1422 107 34 safely safely ADV dti-1422 107 35 in in ADP dti-1422 107 36 advanced advanced ADJ dti-1422 107 37 - - PUNCT dti-1422 107 38 stage stage NOUN dti-1422 107 39 dmn dmn NOUN dti-1422 107 40 patients patient NOUN dti-1422 107 41 taking take VERB dti-1422 107 42 raas raas NOUN dti-1422 107 43 blockers blocker NOUN dti-1422 107 44 . . PUNCT dti-1422 108 1 this this DET dti-1422 108 2 study study NOUN dti-1422 108 3 had have VERB dti-1422 108 4 some some DET dti-1422 108 5 limitations limitation NOUN dti-1422 108 6 . . PUNCT dti-1422 109 1 it it PRON dti-1422 109 2 was be AUX dti-1422 109 3 a a DET dti-1422 109 4 before before NOUN dti-1422 109 5 – – PUNCT dti-1422 109 6 after after ADP dti-1422 109 7 study study NOUN dti-1422 109 8 without without ADP dti-1422 109 9 a a DET dti-1422 109 10 control control NOUN dti-1422 109 11 group group NOUN dti-1422 109 12 , , PUNCT dti-1422 109 13 and and CCONJ dti-1422 109 14 the the DET dti-1422 109 15 number number NOUN dti-1422 109 16 of of ADP dti-1422 109 17 patients patient NOUN dti-1422 109 18 was be AUX dti-1422 109 19 small small ADJ dti-1422 109 20 . . PUNCT dti-1422 110 1 large large ADJ dti-1422 110 2 - - PUNCT dti-1422 110 3 scale scale NOUN dti-1422 110 4 , , PUNCT dti-1422 110 5 double double ADJ dti-1422 110 6 - - PUNCT dti-1422 110 7 blind blind ADJ dti-1422 110 8 trials trial NOUN dti-1422 110 9 with with ADP dti-1422 110 10 an an DET dti-1422 110 11 appropriate appropriate ADJ dti-1422 110 12 control control NOUN dti-1422 110 13 group group NOUN dti-1422 110 14 are be AUX dti-1422 110 15 required require VERB dti-1422 110 16 to to PART dti-1422 110 17 investigate investigate VERB dti-1422 110 18 the the DET dti-1422 110 19 effects effect NOUN dti-1422 110 20 of of ADP dti-1422 110 21 linagliptin linagliptin NOUN dti-1422 110 22 on on ADP dti-1422 110 23 advanced advanced ADJ dti-1422 110 24 - - PUNCT dti-1422 110 25 stage stage NOUN dti-1422 110 26 dmn dmn NOUN dti-1422 110 27 patients patient NOUN dti-1422 110 28 taking take VERB dti-1422 110 29 raas raas NOUN dti-1422 110 30 blockers blocker NOUN dti-1422 110 31 . . PUNCT dti-1422 111 1 in in ADP dti-1422 111 2 conclusion conclusion NOUN dti-1422 111 3 , , PUNCT dti-1422 111 4 linagliptin linagliptin ADJ dti-1422 111 5 as as ADP dti-1422 111 6 an an DET dti-1422 111 7 add add VERB dti-1422 111 8 - - PUNCT dti-1422 111 9 on on ADP dti-1422 111 10 therapy therapy NOUN dti-1422 111 11 significantly significantly ADV dti-1422 111 12 decreased decrease VERB dti-1422 111 13 hba1c hba1c PROPN dti-1422 111 14 and and CCONJ dti-1422 111 15 total total ADJ dti-1422 111 16 cholesterol cholesterol NOUN dti-1422 111 17 levels level NOUN dti-1422 111 18 in in ADP dti-1422 111 19 this this DET dti-1422 111 20 population population NOUN dti-1422 111 21 of of ADP dti-1422 111 22 advanced advanced ADJ dti-1422 111 23 - - PUNCT dti-1422 111 24 stage stage NOUN dti-1422 111 25 dmn dmn NOUN dti-1422 111 26 patients patient NOUN dti-1422 111 27 taking take VERB dti-1422 111 28 raas raas NOUN dti-1422 111 29 blockers blocker NOUN dti-1422 111 30 without without ADP dti-1422 111 31 showing show VERB dti-1422 111 32 any any DET dti-1422 111 33 adverse adverse ADJ dti-1422 111 34 effects effect NOUN dti-1422 111 35 . . PUNCT dti-1422 112 1 our our PRON dti-1422 112 2 results result NOUN dti-1422 112 3 suggest suggest VERB dti-1422 112 4 that that SCONJ dti-1422 112 5 linagliptin linagliptin PROPN dti-1422 112 6 has have VERB dti-1422 112 7 beneficial beneficial ADJ dti-1422 112 8 effects effect NOUN dti-1422 112 9 on on ADP dti-1422 112 10 glucose glucose NOUN dti-1422 112 11 and and CCONJ dti-1422 112 12 lipid lipid NOUN dti-1422 112 13 metabolism metabolism NOUN dti-1422 112 14 and and CCONJ dti-1422 112 15 can can AUX dti-1422 112 16 be be AUX dti-1422 112 17 used use VERB dti-1422 112 18 safely safely ADV dti-1422 112 19 in in ADP dti-1422 112 20 such such ADJ dti-1422 112 21 populations population NOUN dti-1422 112 22 . . PUNCT dti-1422 113 1 acknowledgments acknowledgment NOUN dti-1422 113 2 the the DET dti-1422 113 3 authors author NOUN dti-1422 113 4 wish wish VERB dti-1422 113 5 to to PART dti-1422 113 6 thank thank VERB dti-1422 113 7 the the DET dti-1422 113 8 members member NOUN dti-1422 113 9 of of ADP dti-1422 113 10 the the DET dti-1422 113 11 division division NOUN dti-1422 113 12 of of ADP dti-1422 113 13 nephrology nephrology NOUN dti-1422 113 14 and and CCONJ dti-1422 113 15 the the DET dti-1422 113 16 division division NOUN dti-1422 113 17 of of ADP dti-1422 113 18 endocrinology endocrinology NOUN dti-1422 113 19 and and CCONJ dti-1422 113 20 metabolism metabolism NOUN dti-1422 113 21 , , PUNCT dti-1422 113 22 first first ADJ dti-1422 113 23 department department NOUN dti-1422 113 24 of of ADP dti-1422 113 25 integrated integrate VERB dti-1422 113 26 medicine medicine NOUN dti-1422 113 27 , , PUNCT dti-1422 113 28 saitama saitama PROPN dti-1422 113 29 medical medical ADJ dti-1422 113 30 center center NOUN dti-1422 113 31 , , PUNCT dti-1422 113 32 jichi jichi PROPN dti-1422 113 33 medical medical ADJ dti-1422 113 34 university university PROPN dti-1422 113 35 . . PUNCT dti-1422 114 1 this this DET dti-1422 114 2 study study NOUN dti-1422 114 3 was be AUX dti-1422 114 4 supported support VERB dti-1422 114 5 by by ADP dti-1422 114 6 the the DET dti-1422 114 7 division division NOUN dti-1422 114 8 of of ADP dti-1422 114 9 nephrology nephrology NOUN dti-1422 114 10 , , PUNCT dti-1422 114 11 first first ADJ dti-1422 114 12 department department NOUN dti-1422 114 13 of of ADP dti-1422 114 14 integrated integrate VERB dti-1422 114 15 medicine medicine NOUN dti-1422 114 16 , , PUNCT dti-1422 114 17 saitama saitama PROPN dti-1422 114 18 medical medical ADJ dti-1422 114 19 center center NOUN dti-1422 114 20 , , PUNCT dti-1422 114 21 jichi jichi PROPN dti-1422 114 22 medical medical PROPN dti-1422 114 23 university university PROPN dti-1422 114 24 . . PUNCT dti-1422 115 1 figure figure VERB dti-1422 115 2 4 4 NUM dti-1422 115 3 . . PUNCT dti-1422 116 1 changes change NOUN dti-1422 116 2 in in ADP dti-1422 116 3 total total ADJ dti-1422 116 4 cholesterol cholesterol NOUN dti-1422 116 5 , , PUNCT dti-1422 116 6 ldl ldl NOUN dti-1422 116 7 - - PUNCT dti-1422 116 8 cholesterol cholesterol NOUN dti-1422 116 9 , , PUNCT dti-1422 116 10 hdl hdl NOUN dti-1422 116 11 - - PUNCT dti-1422 116 12 cholesterol cholesterol NOUN dti-1422 116 13 , , PUNCT dti-1422 116 14 and and CCONJ dti-1422 116 15 triglyceride triglyceride INTJ dti-1422 116 16 ( ( PUNCT dti-1422 116 17 all all DET dti-1422 116 18 patients patient NOUN dti-1422 116 19 , , PUNCT dti-1422 116 20 n n NOUN dti-1422 116 21 = = NUM dti-1422 116 22 20 20 NUM dti-1422 116 23 ) ) PUNCT dti-1422 116 24 . . PUNCT dti-1422 117 1 note note VERB dti-1422 117 2 : : PUNCT dti-1422 118 1 * * PUNCT dti-1422 118 2 p p NOUN dti-1422 118 3 , , PUNCT dti-1422 118 4 0.05 0.05 NUM dti-1422 118 5 vs vs ADP dti-1422 118 6 baseline baseline NOUN dti-1422 118 7 . . PUNCT dti-1422 119 1 abbreviations abbreviation NOUN dti-1422 119 2 : : PUNCT dti-1422 119 3 ldl ldl NOUN dti-1422 119 4 , , PUNCT dti-1422 119 5 low low ADJ dti-1422 119 6 - - PUNCT dti-1422 119 7 density density NOUN dti-1422 119 8 lipoprotein lipoprotein NOUN dti-1422 119 9 ; ; PUNCT dti-1422 119 10 hdl hdl X dti-1422 119 11 , , PUNCT dti-1422 119 12 high high ADJ dti-1422 119 13 - - PUNCT dti-1422 119 14 density density NOUN dti-1422 119 15 lipoprotein lipoprotein NOUN dti-1422 119 16 ; ; PUNCT dti-1422 119 17 ns ns NUM dti-1422 119 18 , , PUNCT dti-1422 119 19 not not PART dti-1422 119 20 significant significant ADJ dti-1422 119 21 . . PUNCT dti-1422 120 1 figure figure NOUN dti-1422 120 2 5 5 NUM dti-1422 120 3 . . PUNCT dti-1422 121 1 changes change NOUN dti-1422 121 2 in in ADP dti-1422 121 3 uacr uacr NOUN dti-1422 121 4 and and CCONJ dti-1422 121 5 annual annual ADJ dti-1422 121 6 egfr egfr NOUN dti-1422 121 7 change change NOUN dti-1422 121 8 . . PUNCT dti-1422 122 1 abbreviations abbreviation NOUN dti-1422 122 2 : : PUNCT dti-1422 122 3 uacr uacr ADJ dti-1422 122 4 , , PUNCT dti-1422 122 5 urine urine ADJ dti-1422 122 6 protein protein NOUN dti-1422 122 7 / / SYM dti-1422 122 8 creatinine creatinine NOUN dti-1422 122 9 ratio ratio NOUN dti-1422 122 10 ; ; PUNCT dti-1422 122 11 egfr egfr X dti-1422 122 12 , , PUNCT dti-1422 122 13 estimated estimate VERB dti-1422 122 14 glomerular glomerular ADJ dti-1422 122 15 filtration filtration NOUN dti-1422 122 16 rate rate NOUN dti-1422 122 17 ; ; PUNCT dti-1422 122 18 ns ns X dti-1422 122 19 , , PUNCT dti-1422 122 20 not not PART dti-1422 122 21 significant significant ADJ dti-1422 122 22 . . PUNCT dti-1422 123 1 http://www.la-press.com http://www.la-press.com X dti-1422 123 2 http://www.la-press.com/drug-target-insights-journal-j23 http://www.la-press.com/drug-target-insights-journal-j23 AUX dti-1422 123 3 ueda ueda PROPN dti-1422 123 4 et et PROPN dti-1422 123 5 al al PROPN dti-1422 123 6 18 18 NUM dti-1422 123 7 drug drug NOUN dti-1422 123 8 target target NOUN dti-1422 123 9 insights insight NOUN dti-1422 123 10 2016:10 2016:10 NUM dti-1422 123 11 author author NOUN dti-1422 123 12 contributions contribution NOUN dti-1422 123 13 conceived conceive VERB dti-1422 123 14 and and CCONJ dti-1422 123 15 designed design VERB dti-1422 123 16 the the DET dti-1422 123 17 experiments experiment NOUN dti-1422 123 18 : : PUNCT dti-1422 123 19 hi hi INTJ dti-1422 123 20 , , PUNCT dti-1422 123 21 tk tk PROPN dti-1422 123 22 , , PUNCT dti-1422 123 23 ms ms PROPN dti-1422 123 24 , , PUNCT dti-1422 123 25 hm hm INTJ dti-1422 123 26 , , PUNCT dti-1422 123 27 ki ki PROPN dti-1422 123 28 , , PUNCT dti-1422 123 29 kh kh PROPN dti-1422 123 30 , , PUNCT dti-1422 123 31 yk yk PROPN dti-1422 123 32 , , PUNCT dti-1422 123 33 hm hm INTJ dti-1422 123 34 , , PUNCT dti-1422 123 35 th th NOUN dti-1422 123 36 , , PUNCT dti-1422 123 37 so so ADV dti-1422 123 38 , , PUNCT dti-1422 123 39 mk mk PROPN dti-1422 123 40 , , PUNCT dti-1422 123 41 kt kt PROPN dti-1422 123 42 , , PUNCT dti-1422 123 43 and and CCONJ dti-1422 123 44 ym ym PROPN dti-1422 123 45 . . PROPN dti-1422 123 46 analyzed analyze VERB dti-1422 123 47 the the DET dti-1422 123 48 data datum NOUN dti-1422 123 49 : : PUNCT dti-1422 123 50 yu yu PROPN dti-1422 123 51 , , PUNCT dti-1422 123 52 so so ADV dti-1422 123 53 , , PUNCT dti-1422 123 54 and and CCONJ dti-1422 123 55 ym ym PROPN dti-1422 123 56 . . PROPN dti-1422 123 57 wrote write VERB dti-1422 123 58 the the DET dti-1422 123 59 first first ADJ dti-1422 123 60 draft draft NOUN dti-1422 123 61 of of ADP dti-1422 123 62 the the DET dti-1422 123 63 manuscript manuscript NOUN dti-1422 123 64 : : PUNCT dti-1422 123 65 yu yu PROPN dti-1422 123 66 . . PROPN dti-1422 123 67 contributed contribute VERB dti-1422 123 68 to to ADP dti-1422 123 69 writing write VERB dti-1422 123 70 the the DET dti-1422 123 71 manuscript manuscript NOUN dti-1422 123 72 : : PUNCT dti-1422 123 73 so so ADV dti-1422 123 74 . . PUNCT dti-1422 124 1 agreed agree VERB dti-1422 124 2 with with ADP dti-1422 124 3 manuscript manuscript NOUN dti-1422 124 4 results result NOUN dti-1422 124 5 and and CCONJ dti-1422 124 6 conclusions conclusion NOUN dti-1422 124 7 : : PUNCT dti-1422 124 8 hi hi INTJ dti-1422 124 9 , , PUNCT dti-1422 124 10 tk tk PROPN dti-1422 124 11 , , PUNCT dti-1422 124 12 ms ms PROPN dti-1422 124 13 , , PUNCT dti-1422 124 14 hm hm INTJ dti-1422 124 15 , , PUNCT dti-1422 124 16 ki ki PROPN dti-1422 124 17 , , PUNCT dti-1422 124 18 kh kh PROPN dti-1422 124 19 , , PUNCT dti-1422 124 20 yk yk PROPN dti-1422 124 21 , , PUNCT dti-1422 124 22 hm hm INTJ dti-1422 124 23 , , PUNCT dti-1422 124 24 th th NOUN dti-1422 124 25 , , PUNCT dti-1422 124 26 so so ADV dti-1422 124 27 , , PUNCT dti-1422 124 28 mk mk PROPN dti-1422 124 29 , , PUNCT dti-1422 124 30 kt kt PROPN dti-1422 124 31 , , PUNCT dti-1422 124 32 and and CCONJ dti-1422 124 33 ym ym X dti-1422 124 34 . . PUNCT dti-1422 125 1 jointly jointly ADV dti-1422 125 2 developed develop VERB dti-1422 125 3 the the DET dti-1422 125 4 structure structure NOUN dti-1422 125 5 and and CCONJ dti-1422 125 6 arguments argument NOUN dti-1422 125 7 for for ADP dti-1422 125 8 the the DET dti-1422 125 9 paper paper NOUN dti-1422 125 10 : : PUNCT dti-1422 125 11 hi hi INTJ dti-1422 125 12 , , PUNCT dti-1422 125 13 tk tk PROPN dti-1422 125 14 , , PUNCT dti-1422 125 15 ms ms PROPN dti-1422 125 16 , , PUNCT dti-1422 125 17 hm hm INTJ dti-1422 125 18 , , PUNCT dti-1422 125 19 ki ki PROPN dti-1422 125 20 , , PUNCT dti-1422 125 21 kh kh PROPN dti-1422 125 22 , , PUNCT dti-1422 125 23 yk yk PROPN dti-1422 125 24 , , PUNCT dti-1422 125 25 hm hm INTJ dti-1422 125 26 , , PUNCT dti-1422 125 27 th th NOUN dti-1422 125 28 , , PUNCT dti-1422 125 29 so so ADV dti-1422 125 30 , , PUNCT dti-1422 125 31 mk mk PROPN dti-1422 125 32 , , PUNCT dti-1422 125 33 kt kt PROPN dti-1422 125 34 , , PUNCT dti-1422 125 35 and and CCONJ dti-1422 125 36 ym ym PROPN dti-1422 125 37 . . PUNCT dti-1422 125 38 made make VERB dti-1422 125 39 critical critical ADJ dti-1422 125 40 revisions revision NOUN dti-1422 125 41 and and CCONJ dti-1422 125 42 approved approve VERB dti-1422 125 43 the the DET dti-1422 125 44 final final ADJ dti-1422 125 45 version version NOUN dti-1422 125 46 : : PUNCT dti-1422 125 47 ym ym X dti-1422 125 48 . . PUNCT dti-1422 126 1 all all DET dti-1422 126 2 authors author NOUN dti-1422 126 3 reviewed review VERB dti-1422 126 4 and and CCONJ dti-1422 126 5 approved approve VERB dti-1422 126 6 the the DET dti-1422 126 7 final final ADJ dti-1422 126 8 manuscript manuscript NOUN dti-1422 126 9 . . PUNCT dti-1422 127 1 references reference NOUN dti-1422 127 2 1 1 NUM dti-1422 127 3 . . PUNCT dti-1422 127 4 grassmann grassmann PROPN dti-1422 127 5 a a DET dti-1422 127 6 , , PUNCT dti-1422 127 7 gioberge gioberge NOUN dti-1422 127 8 s s PROPN dti-1422 127 9 , , PUNCT dti-1422 127 10 moeller moeller PROPN dti-1422 127 11 s s PROPN dti-1422 127 12 , , PUNCT dti-1422 127 13 brown brown ADJ dti-1422 127 14 g. g. PROPN dti-1422 127 15 esrd esrd PROPN dti-1422 127 16 patients patient NOUN dti-1422 127 17 in in ADP dti-1422 127 18 2004 2004 NUM dti-1422 127 19 : : PUNCT dti-1422 127 20 global global ADJ dti-1422 127 21 overview overview NOUN dti-1422 127 22 of of ADP dti-1422 127 23 patient patient ADJ dti-1422 127 24 numbers number NOUN dti-1422 127 25 , , PUNCT dti-1422 127 26 treatment treatment NOUN dti-1422 127 27 modalities modality NOUN dti-1422 127 28 and and CCONJ dti-1422 127 29 associated associated ADJ dti-1422 127 30 trends trend NOUN dti-1422 127 31 . . PUNCT dti-1422 128 1 nephrol nephrol PROPN dti-1422 128 2 dial dial NOUN dti-1422 128 3 transplant transplant NOUN dti-1422 128 4 . . PUNCT dti-1422 129 1 2005;20(12):2587–2593 2005;20(12):2587–2593 NUM dti-1422 129 2 . . X dti-1422 130 1 2 2 NUM dti-1422 130 2 . . X dti-1422 130 3 atkins atkins PROPN dti-1422 130 4 rc rc PROPN dti-1422 130 5 . . PUNCT dti-1422 131 1 the the DET dti-1422 131 2 epidemiology epidemiology NOUN dti-1422 131 3 of of ADP dti-1422 131 4 chronic chronic ADJ dti-1422 131 5 kidney kidney NOUN dti-1422 131 6 disease disease NOUN dti-1422 131 7 . . PUNCT dti-1422 132 1 kidney kidney NOUN dti-1422 132 2 int int PROPN dti-1422 132 3 suppl suppl PROPN dti-1422 132 4 . . PUNCT dti-1422 132 5 2005 2005 NUM dti-1422 132 6 ; ; PUNCT dti-1422 132 7 67(94):s14 67(94):s14 NUM dti-1422 132 8 – – PUNCT dti-1422 132 9 s18 s18 NOUN dti-1422 132 10 . . PUNCT dti-1422 133 1 3 3 X dti-1422 133 2 . . X dti-1422 133 3 molitch molitch VERB dti-1422 133 4 me i PRON dti-1422 133 5 , , PUNCT dti-1422 133 6 defronzo defronzo NOUN dti-1422 133 7 ra ra PROPN dti-1422 133 8 , , PUNCT dti-1422 133 9 franz franz PROPN dti-1422 133 10 mj mj PROPN dti-1422 133 11 , , PUNCT dti-1422 133 12 et et PROPN dti-1422 133 13 al al PROPN dti-1422 133 14 . . PROPN dti-1422 133 15 nephropathy nephropathy NOUN dti-1422 133 16 in in ADP dti-1422 133 17 diabetes diabetes NOUN dti-1422 133 18 . . PUNCT dti-1422 134 1 diabetes diabetes NOUN dti-1422 134 2 care care NOUN dti-1422 134 3 . . PUNCT dti-1422 135 1 2004;27(suppl 2004;27(suppl PROPN dti-1422 135 2 1):s79 1):s79 NUM dti-1422 135 3 – – PUNCT dti-1422 135 4 s83 s83 NOUN dti-1422 135 5 . . PUNCT dti-1422 136 1 4 4 X dti-1422 136 2 . . X dti-1422 136 3 preis preis PROPN dti-1422 136 4 sr sr PROPN dti-1422 136 5 , , PUNCT dti-1422 136 6 hwang hwang PROPN dti-1422 136 7 sj sj PROPN dti-1422 136 8 , , PUNCT dti-1422 136 9 coady coady PROPN dti-1422 136 10 s s PROPN dti-1422 136 11 , , PUNCT dti-1422 136 12 et et PROPN dti-1422 136 13 al al PROPN dti-1422 136 14 . . PUNCT dti-1422 136 15 trends trend NOUN dti-1422 136 16 in in ADP dti-1422 136 17 all all DET dti-1422 136 18 - - PUNCT dti-1422 136 19 cause cause NOUN dti-1422 136 20 and and CCONJ dti-1422 136 21 cardiovascular cardiovascular ADJ dti-1422 136 22 disease disease NOUN dti-1422 136 23 mortality mortality NOUN dti-1422 136 24 among among ADP dti-1422 136 25 women woman NOUN dti-1422 136 26 and and CCONJ dti-1422 136 27 men man NOUN dti-1422 136 28 with with ADP dti-1422 136 29 and and CCONJ dti-1422 136 30 without without ADP dti-1422 136 31 diabetes diabetes NOUN dti-1422 136 32 mellitus mellitus NOUN dti-1422 136 33 in in ADP dti-1422 136 34 the the DET dti-1422 136 35 framingham framingham PROPN dti-1422 136 36 heart heart PROPN dti-1422 136 37 study study NOUN dti-1422 136 38 , , PUNCT dti-1422 136 39 1950 1950 NUM dti-1422 136 40 to to ADP dti-1422 136 41 2005 2005 NUM dti-1422 136 42 . . PUNCT dti-1422 137 1 circulation circulation NOUN dti-1422 137 2 . . PUNCT dti-1422 138 1 2009;119(13):1728–1735 2009;119(13):1728–1735 NUM dti-1422 138 2 . . NOUN dti-1422 138 3 5 5 NUM dti-1422 138 4 . . X dti-1422 138 5 ohkubo ohkubo PROPN dti-1422 138 6 y y PROPN dti-1422 138 7 , , PUNCT dti-1422 138 8 kishikawa kishikawa PROPN dti-1422 138 9 h h PROPN dti-1422 138 10 , , PUNCT dti-1422 138 11 araki araki PROPN dti-1422 138 12 e e PROPN dti-1422 138 13 , , PUNCT dti-1422 138 14 et et PROPN dti-1422 138 15 al al PROPN dti-1422 138 16 . . PROPN dti-1422 139 1 intensive intensive ADJ dti-1422 139 2 insulin insulin NOUN dti-1422 139 3 therapy therapy NOUN dti-1422 139 4 prevents prevent VERB dti-1422 139 5 the the DET dti-1422 139 6 progression progression NOUN dti-1422 139 7 of of ADP dti-1422 139 8 diabetic diabetic ADJ dti-1422 139 9 microvascular microvascular ADJ dti-1422 139 10 complications complication NOUN dti-1422 139 11 in in ADP dti-1422 139 12 japanese japanese ADJ dti-1422 139 13 patients patient NOUN dti-1422 139 14 with with ADP dti-1422 139 15 non non ADJ dti-1422 139 16 - - ADJ dti-1422 139 17 insulin insulin ADJ dti-1422 139 18 - - PUNCT dti-1422 139 19 dependent dependent ADJ dti-1422 139 20 diabetes diabetes NOUN dti-1422 139 21 mellitus mellitus NOUN dti-1422 139 22 : : PUNCT dti-1422 139 23 a a DET dti-1422 139 24 randomized randomized ADJ dti-1422 139 25 prospective prospective ADJ dti-1422 139 26 6 6 NUM dti-1422 139 27 - - PUNCT dti-1422 139 28 year year NOUN dti-1422 139 29 study study NOUN dti-1422 139 30 . . PUNCT dti-1422 140 1 diabetes diabetes NOUN dti-1422 140 2 res re VERB dti-1422 140 3 clin clin PROPN dti-1422 140 4 pract pract PROPN dti-1422 140 5 . . PUNCT dti-1422 141 1 1995;28(2):103–117 1995;28(2):103–117 NUM dti-1422 141 2 . . NOUN dti-1422 142 1 6 6 NUM dti-1422 142 2 . . PUNCT dti-1422 142 3 intensive intensive ADJ dti-1422 142 4 blood blood NOUN dti-1422 142 5 - - PUNCT dti-1422 142 6 glucose glucose NOUN dti-1422 142 7 control control NOUN dti-1422 142 8 with with ADP dti-1422 142 9 sulphonylureas sulphonylurea NOUN dti-1422 142 10 or or CCONJ dti-1422 142 11 insulin insulin NOUN dti-1422 142 12 compared compare VERB dti-1422 142 13 with with ADP dti-1422 142 14 conventional conventional ADJ dti-1422 142 15 treatment treatment NOUN dti-1422 142 16 and and CCONJ dti-1422 142 17 risk risk NOUN dti-1422 142 18 of of ADP dti-1422 142 19 complications complication NOUN dti-1422 142 20 in in ADP dti-1422 142 21 patients patient NOUN dti-1422 142 22 with with ADP dti-1422 142 23 type type NOUN dti-1422 142 24 2 2 NUM dti-1422 142 25 diabetes diabetes NOUN dti-1422 142 26 ( ( PUNCT dti-1422 142 27 ukpds ukpds NOUN dti-1422 142 28 33 33 NUM dti-1422 142 29 ) ) PUNCT dti-1422 142 30 . . PUNCT dti-1422 143 1 uk uk PROPN dti-1422 143 2 prospective prospective ADJ dti-1422 143 3 diabetes diabetes NOUN dti-1422 143 4 study study NOUN dti-1422 143 5 ( ( PUNCT dti-1422 143 6 ukpds ukpds PROPN dti-1422 143 7 ) ) PUNCT dti-1422 143 8 group group NOUN dti-1422 143 9 . . PUNCT dti-1422 144 1 lancet lancet PROPN dti-1422 144 2 . . PUNCT dti-1422 145 1 1998 1998 NUM dti-1422 145 2 ; ; PUNCT dti-1422 145 3 352(9131):837–853 352(9131):837–853 NUM dti-1422 145 4 . . PUNCT dti-1422 146 1 7 7 X dti-1422 146 2 . . X dti-1422 146 3 boussageon boussageon NOUN dti-1422 146 4 r r NOUN dti-1422 146 5 , , PUNCT dti-1422 146 6 bejan bejan NOUN dti-1422 146 7 - - PUNCT dti-1422 146 8 angoulvant angoulvant NOUN dti-1422 146 9 t t PROPN dti-1422 146 10 , , PUNCT dti-1422 146 11 saadatian saadatian PROPN dti-1422 146 12 - - PUNCT dti-1422 146 13 elahi elahi PROPN dti-1422 146 14 m m PROPN dti-1422 146 15 , , PUNCT dti-1422 146 16 et et PROPN dti-1422 146 17 al al PROPN dti-1422 146 18 . . PROPN dti-1422 146 19 effect effect NOUN dti-1422 146 20 of of ADP dti-1422 146 21 intensive intensive ADJ dti-1422 146 22 glucose glucose NOUN dti-1422 146 23 lowering lower VERB dti-1422 146 24 treatment treatment NOUN dti-1422 146 25 on on ADP dti-1422 146 26 all all DET dti-1422 146 27 cause cause NOUN dti-1422 146 28 mortality mortality NOUN dti-1422 146 29 , , PUNCT dti-1422 146 30 cardiovascular cardiovascular ADJ dti-1422 146 31 death death NOUN dti-1422 146 32 , , PUNCT dti-1422 146 33 and and CCONJ dti-1422 146 34 microvascular microvascular ADJ dti-1422 146 35 events event NOUN dti-1422 146 36 in in ADP dti-1422 146 37 type type NOUN dti-1422 146 38 2 2 NUM dti-1422 146 39 diabetes diabetes NOUN dti-1422 146 40 : : PUNCT dti-1422 146 41 meta meta ADJ dti-1422 146 42 - - PUNCT dti-1422 146 43 analysis analysis NOUN dti-1422 146 44 of of ADP dti-1422 146 45 randomised randomised ADJ dti-1422 146 46 controlled control VERB dti-1422 146 47 trials trial NOUN dti-1422 146 48 . . PUNCT dti-1422 147 1 bmj bmj PROPN dti-1422 147 2 . . PUNCT dti-1422 148 1 2011;343 2011;343 NOUN dti-1422 148 2 : : PUNCT dti-1422 148 3 d4169 d4169 PROPN dti-1422 148 4 . . PROPN dti-1422 148 5 8 8 NUM dti-1422 148 6 . . PUNCT dti-1422 149 1 araki araki PROPN dti-1422 149 2 s s PROPN dti-1422 149 3 , , PUNCT dti-1422 149 4 haneda haneda PROPN dti-1422 149 5 m m PROPN dti-1422 149 6 , , PUNCT dti-1422 149 7 koya koya PROPN dti-1422 149 8 d d PROPN dti-1422 149 9 , , PUNCT dti-1422 149 10 et et PROPN dti-1422 149 11 al al PROPN dti-1422 149 12 . . PROPN dti-1422 149 13 reduction reduction NOUN dti-1422 149 14 in in ADP dti-1422 149 15 microalbuminuria microalbuminuria PROPN dti-1422 149 16 as as ADP dti-1422 149 17 an an DET dti-1422 149 18 integrated integrated ADJ dti-1422 149 19 indicator indicator NOUN dti-1422 149 20 for for ADP dti-1422 149 21 renal renal ADJ dti-1422 149 22 and and CCONJ dti-1422 149 23 cardiovascular cardiovascular ADJ dti-1422 149 24 risk risk NOUN dti-1422 149 25 reduction reduction NOUN dti-1422 149 26 in in ADP dti-1422 149 27 patients patient NOUN dti-1422 149 28 with with ADP dti-1422 149 29 type type NOUN dti-1422 149 30 2 2 NUM dti-1422 149 31 diabetes diabetes NOUN dti-1422 149 32 . . PUNCT dti-1422 150 1 diabetes diabetes NOUN dti-1422 150 2 . . PUNCT dti-1422 151 1 2007;56(6):1727–1730 2007;56(6):1727–1730 ADJ dti-1422 151 2 . . PUNCT dti-1422 152 1 9 9 X dti-1422 152 2 . . X dti-1422 152 3 heerspink heerspink PROPN dti-1422 152 4 hj hj PROPN dti-1422 152 5 , , PUNCT dti-1422 152 6 ninomiya ninomiya PROPN dti-1422 152 7 t t PROPN dti-1422 152 8 , , PUNCT dti-1422 152 9 perkovic perkovic PROPN dti-1422 152 10 v v NOUN dti-1422 152 11 , , PUNCT dti-1422 152 12 et et PROPN dti-1422 152 13 al al PROPN dti-1422 152 14 . . PUNCT dti-1422 152 15 effects effect NOUN dti-1422 152 16 of of ADP dti-1422 152 17 a a DET dti-1422 152 18 fixed fix VERB dti-1422 152 19 combination combination NOUN dti-1422 152 20 of of ADP dti-1422 152 21 perindopril perindopril ADJ dti-1422 152 22 and and CCONJ dti-1422 152 23 indapamide indapamide NOUN dti-1422 152 24 in in ADP dti-1422 152 25 patients patient NOUN dti-1422 152 26 with with ADP dti-1422 152 27 type type NOUN dti-1422 152 28 2 2 NUM dti-1422 152 29 diabetes diabetes NOUN dti-1422 152 30 and and CCONJ dti-1422 152 31 chronic chronic ADJ dti-1422 152 32 kidney kidney NOUN dti-1422 152 33 disease disease NOUN dti-1422 152 34 . . PUNCT dti-1422 153 1 eur eur PROPN dti-1422 153 2 heart heart NOUN dti-1422 153 3 j. j. PROPN dti-1422 153 4 2010;31(23):2888–2896 2010;31(23):2888–2896 PROPN dti-1422 153 5 . . PROPN dti-1422 154 1 10 10 NUM dti-1422 154 2 . . PUNCT dti-1422 154 3 benedict benedict PROPN dti-1422 154 4 group group PROPN dti-1422 154 5 . . PUNCT dti-1422 155 1 the the DET dti-1422 155 2 bergamo bergamo NOUN dti-1422 155 3 nephrologic nephrologic ADJ dti-1422 155 4 diabetes diabetes NOUN dti-1422 155 5 complications complication NOUN dti-1422 155 6 trial trial NOUN dti-1422 155 7 ( ( PUNCT dti-1422 155 8 benedict benedict NOUN dti-1422 155 9 ): ): PUNCT dti-1422 155 10 design design NOUN dti-1422 155 11 and and CCONJ dti-1422 155 12 baseline baseline NOUN dti-1422 155 13 characteristics characteristic NOUN dti-1422 155 14 . . PUNCT dti-1422 156 1 control control PROPN dti-1422 156 2 clin clin PROPN dti-1422 156 3 trials trial NOUN dti-1422 156 4 . . PUNCT dti-1422 157 1 2003 2003 NUM dti-1422 157 2 ; ; PUNCT dti-1422 157 3 24(4):442–461 24(4):442–461 X dti-1422 157 4 . . NOUN dti-1422 157 5 11 11 NUM dti-1422 157 6 . . PUNCT dti-1422 158 1 brenner brenner PROPN dti-1422 158 2 bm bm PROPN dti-1422 158 3 , , PUNCT dti-1422 158 4 cooper cooper PROPN dti-1422 158 5 me i PRON dti-1422 158 6 , , PUNCT dti-1422 158 7 de de X dti-1422 158 8 zeeuw zeeuw PROPN dti-1422 158 9 d d PROPN dti-1422 158 10 , , PUNCT dti-1422 158 11 et et PROPN dti-1422 158 12 al al PROPN dti-1422 158 13 . . PUNCT dti-1422 158 14 effects effect NOUN dti-1422 158 15 of of ADP dti-1422 158 16 losartan losartan ADJ dti-1422 158 17 on on ADP dti-1422 158 18 renal renal ADJ dti-1422 158 19 and and CCONJ dti-1422 158 20 cardiovascular cardiovascular ADJ dti-1422 158 21 outcomes outcome NOUN dti-1422 158 22 in in ADP dti-1422 158 23 patients patient NOUN dti-1422 158 24 with with ADP dti-1422 158 25 type type NOUN dti-1422 158 26 2 2 NUM dti-1422 158 27 diabetes diabetes NOUN dti-1422 158 28 and and CCONJ dti-1422 158 29 nephropathy nephropathy NOUN dti-1422 158 30 . . PUNCT dti-1422 159 1 n n CCONJ dti-1422 159 2     SPACE dti-1422 159 3 engl engl PROPN dti-1422 159 4 j j PROPN dti-1422 159 5 med med PROPN dti-1422 159 6 . . PUNCT dti-1422 160 1 2001;345(12):861–869 2001;345(12):861–869 NUM dti-1422 160 2 . . NOUN dti-1422 160 3 12 12 NUM dti-1422 160 4 . . PUNCT dti-1422 161 1 chalmers chalmers PROPN dti-1422 161 2 j j PROPN dti-1422 161 3 , , PUNCT dti-1422 161 4 joshi joshi PROPN dti-1422 161 5 r r PROPN dti-1422 161 6 , , PUNCT dti-1422 161 7 kengne kengne PROPN dti-1422 161 8 ap ap PROPN dti-1422 161 9 , , PUNCT dti-1422 162 1 macmahon macmahon PROPN dti-1422 162 2 s. s. PROPN dti-1422 162 3 blood blood NOUN dti-1422 162 4 pressure pressure NOUN dti-1422 162 5 lowering lower VERB dti-1422 162 6 with with ADP dti-1422 162 7 fixed fix VERB dti-1422 162 8 combination combination NOUN dti-1422 162 9 perindopril perindopril ADJ dti-1422 162 10 - - PUNCT dti-1422 162 11 indapamide indapamide NOUN dti-1422 162 12 : : PUNCT dti-1422 162 13 key key ADJ dti-1422 162 14 findings finding NOUN dti-1422 162 15 from from ADP dti-1422 162 16 advance advance NOUN dti-1422 162 17 . . PUNCT dti-1422 163 1 j j NOUN dti-1422 163 2     SPACE dti-1422 163 3 hypertens hyperten NOUN dti-1422 163 4 suppl suppl PROPN dti-1422 163 5 . . PUNCT dti-1422 164 1 2008;26(2):s11 2008;26(2):s11 NUM dti-1422 164 2 – – PUNCT dti-1422 164 3 s15 s15 NOUN dti-1422 164 4 . . PUNCT dti-1422 165 1 13 13 NUM dti-1422 165 2 . . PUNCT dti-1422 166 1 chahal chahal PROPN dti-1422 166 2 h h PROPN dti-1422 166 3 , , PUNCT dti-1422 166 4 chowdhury chowdhury PROPN dti-1422 166 5 ta ta PROPN dti-1422 166 6 . . PUNCT dti-1422 167 1 gliptins gliptin NOUN dti-1422 167 2 : : PUNCT dti-1422 167 3 a a DET dti-1422 167 4 new new ADJ dti-1422 167 5 class class NOUN dti-1422 167 6 of of ADP dti-1422 167 7 oral oral ADJ dti-1422 167 8 hypoglycaemic hypoglycaemic ADJ dti-1422 167 9 agent agent NOUN dti-1422 167 10 . . PUNCT dti-1422 168 1 qjm qjm INTJ dti-1422 168 2 . . PUNCT dti-1422 169 1 2007;100(11):671–677 2007;100(11):671–677 X dti-1422 169 2 . . PUNCT dti-1422 170 1 14 14 NUM dti-1422 170 2 . . PUNCT dti-1422 171 1 ahren ahren PROPN dti-1422 171 2 b. b. PROPN dti-1422 171 3 dpp-4 dpp-4 PART dti-1422 171 4 inhibitors inhibitor NOUN dti-1422 171 5 . . PUNCT dti-1422 172 1 best good ADJ dti-1422 172 2 pract pract PROPN dti-1422 172 3 res re NOUN dti-1422 172 4 clin clin PROPN dti-1422 172 5 endocrinol endocrinol NOUN dti-1422 172 6 metab metab NOUN dti-1422 172 7 . . PUNCT dti-1422 173 1 2007;21(4 2007;21(4 NUM dti-1422 173 2 ): ): PUNCT dti-1422 174 1 517–533 517–533 NUM dti-1422 174 2 . . PUNCT dti-1422 174 3 15 15 NUM dti-1422 174 4 . . PUNCT dti-1422 174 5 deacon deacon NOUN dti-1422 174 6 cf cf PROPN dti-1422 174 7 , , PUNCT dti-1422 174 8 holst holst NOUN dti-1422 174 9 jj jj PROPN dti-1422 174 10 . . PROPN dti-1422 174 11 linagliptin linagliptin PROPN dti-1422 174 12 , , PUNCT dti-1422 174 13 a a DET dti-1422 174 14 xanthine xanthine NOUN dti-1422 174 15 - - PUNCT dti-1422 174 16 based base VERB dti-1422 174 17 dipeptidyl dipeptidyl NOUN dti-1422 174 18 peptidase-4 peptidase-4 X dti-1422 174 19 inhibitor inhibitor NOUN dti-1422 174 20 with with ADP dti-1422 174 21 an an DET dti-1422 174 22 unusual unusual ADJ dti-1422 174 23 profile profile NOUN dti-1422 174 24 for for ADP dti-1422 174 25 the the DET dti-1422 174 26 treatment treatment NOUN dti-1422 174 27 of of ADP dti-1422 174 28 type type NOUN dti-1422 174 29 2 2 NUM dti-1422 174 30 diabetes diabetes NOUN dti-1422 174 31 . . PUNCT dti-1422 175 1 expert expert NOUN dti-1422 175 2 opin opin NOUN dti-1422 175 3 investig investig NOUN dti-1422 175 4 drugs drug NOUN dti-1422 175 5 . . PUNCT dti-1422 176 1 2010;19(1):133–140 2010;19(1):133–140 NUM dti-1422 176 2 . . NOUN dti-1422 176 3 16 16 NUM dti-1422 176 4 . . PUNCT dti-1422 176 5 graefe graefe NOUN dti-1422 176 6 - - PUNCT dti-1422 176 7 mody mody NOUN dti-1422 176 8 u u NOUN dti-1422 176 9 , , PUNCT dti-1422 176 10 friedrich friedrich PROPN dti-1422 176 11 c c NOUN dti-1422 176 12 , , PUNCT dti-1422 176 13 port port NOUN dti-1422 176 14 a a X dti-1422 176 15 , , PUNCT dti-1422 176 16 et et PROPN dti-1422 176 17 al al PROPN dti-1422 176 18 . . PROPN dti-1422 176 19 effect effect NOUN dti-1422 176 20 of of ADP dti-1422 176 21 renal renal ADJ dti-1422 176 22 impairment impairment NOUN dti-1422 176 23 on on ADP dti-1422 176 24 the the DET dti-1422 176 25 pharmacokinetics pharmacokinetic NOUN dti-1422 176 26 of of ADP dti-1422 176 27 the the DET dti-1422 176 28 dipeptidyl dipeptidyl NOUN dti-1422 176 29 peptidase-4 peptidase-4 PRON dti-1422 176 30 inhibitor inhibitor NOUN dti-1422 176 31 linagliptin linagliptin ADJ dti-1422 176 32 . . PUNCT dti-1422 177 1 diabetes diabetes NOUN dti-1422 177 2 obes obe VERB dti-1422 177 3 metab metab NOUN dti-1422 177 4 . . PUNCT dti-1422 178 1 2011;13(10):939–946 2011;13(10):939–946 NUM dti-1422 178 2 . . PUNCT dti-1422 179 1 17 17 NUM dti-1422 179 2 . . PUNCT dti-1422 180 1 laakso laakso PROPN dti-1422 180 2 m m PROPN dti-1422 180 3 , , PUNCT dti-1422 180 4 rosenstock rosenstock PROPN dti-1422 180 5 j j PROPN dti-1422 180 6 , , PUNCT dti-1422 180 7 groop groop PROPN dti-1422 180 8 ph ph PROPN dti-1422 180 9 , , PUNCT dti-1422 180 10 et et PROPN dti-1422 180 11 al al PROPN dti-1422 180 12 . . PUNCT dti-1422 180 13 treatment treatment NOUN dti-1422 180 14 with with ADP dti-1422 180 15 the the DET dti-1422 180 16 dipeptidyl dipeptidyl NOUN dti-1422 180 17 peptidase-4 peptidase-4 PRON dti-1422 180 18 inhibitor inhibitor NOUN dti-1422 180 19 linagliptin linagliptin ADJ dti-1422 180 20 or or CCONJ dti-1422 180 21 placebo placebo NOUN dti-1422 180 22 followed follow VERB dti-1422 180 23 by by ADP dti-1422 180 24 glimepiride glimepiride NOUN dti-1422 180 25 in in ADP dti-1422 180 26 patients patient NOUN dti-1422 180 27 with with ADP dti-1422 180 28 type type NOUN dti-1422 180 29 2 2 NUM dti-1422 180 30 diabetes diabetes NOUN dti-1422 180 31 with with ADP dti-1422 180 32 moderate moderate ADJ dti-1422 180 33 to to ADP dti-1422 180 34 severe severe ADJ dti-1422 180 35 renal renal ADJ dti-1422 180 36 impairment impairment NOUN dti-1422 180 37 : : PUNCT dti-1422 180 38 a a PRON dti-1422 180 39 52 52 NUM dti-1422 180 40 - - PUNCT dti-1422 180 41 week week NOUN dti-1422 180 42 , , PUNCT dti-1422 180 43 randomized randomize VERB dti-1422 180 44 , , PUNCT dti-1422 180 45 double double ADJ dti-1422 180 46 - - PUNCT dti-1422 180 47 blind blind ADJ dti-1422 180 48 clinical clinical ADJ dti-1422 180 49 trial trial NOUN dti-1422 180 50 . . PUNCT dti-1422 181 1 diabetes diabetes NOUN dti-1422 181 2 care care NOUN dti-1422 181 3 . . PUNCT dti-1422 182 1 2015;38(2):e15 2015;38(2):e15 X dti-1422 182 2 – – PUNCT dti-1422 182 3 e17 e17 NOUN dti-1422 182 4 . . PUNCT dti-1422 183 1 18 18 NUM dti-1422 183 2 . . PUNCT dti-1422 184 1 owens owens PROPN dti-1422 184 2 dr dr PROPN dti-1422 184 3 , , PUNCT dti-1422 184 4 swallow swallow NOUN dti-1422 184 5 r r NOUN dti-1422 184 6 , , PUNCT dti-1422 184 7 dugi dugi PROPN dti-1422 184 8 ka ka PROPN dti-1422 184 9 , , PUNCT dti-1422 184 10 woerle woerle PROPN dti-1422 184 11 hj hj PROPN dti-1422 184 12 . . PROPN dti-1422 184 13 efficacy efficacy NOUN dti-1422 184 14 and and CCONJ dti-1422 184 15 safety safety NOUN dti-1422 184 16 of of ADP dti-1422 184 17 linagliptin linagliptin NOUN dti-1422 184 18 in in ADP dti-1422 184 19 persons person NOUN dti-1422 184 20 with with ADP dti-1422 184 21 type type NOUN dti-1422 184 22 2 2 NUM dti-1422 184 23 diabetes diabetes NOUN dti-1422 184 24 inadequately inadequately ADV dti-1422 184 25 controlled control VERB dti-1422 184 26 by by ADP dti-1422 184 27 a a DET dti-1422 184 28 combination combination NOUN dti-1422 184 29 of of ADP dti-1422 184 30 metformin metformin NOUN dti-1422 184 31 and and CCONJ dti-1422 184 32 sulphonylurea sulphonylurea PROPN dti-1422 184 33 : : PUNCT dti-1422 184 34 a a DET dti-1422 184 35 24 24 NUM dti-1422 184 36 - - PUNCT dti-1422 184 37 week week NOUN dti-1422 184 38 randomized randomized ADJ dti-1422 184 39 study study NOUN dti-1422 184 40 . . PUNCT dti-1422 185 1 diabet diabet PROPN dti-1422 185 2 med med PROPN dti-1422 185 3 . . PUNCT dti-1422 185 4 2011 2011 NUM dti-1422 185 5 ; ; PUNCT dti-1422 185 6 28(11):1352–1361 28(11):1352–1361 NOUN dti-1422 185 7 . . PUNCT dti-1422 186 1 19 19 NUM dti-1422 186 2 . . NOUN dti-1422 186 3 haak haak PROPN dti-1422 186 4 t t PROPN dti-1422 186 5 , , PUNCT dti-1422 186 6 meinicke meinicke PROPN dti-1422 186 7 t t PROPN dti-1422 186 8 , , PUNCT dti-1422 186 9 jones jones PROPN dti-1422 186 10 r r PROPN dti-1422 186 11 , , PUNCT dti-1422 186 12 weber weber PROPN dti-1422 186 13 s s PROPN dti-1422 186 14 , , PUNCT dti-1422 186 15 von von PROPN dti-1422 186 16 eynatten eynatten VERB dti-1422 186 17 m m PROPN dti-1422 186 18 , , PUNCT dti-1422 186 19 woerle woerle PROPN dti-1422 186 20 hj hj PROPN dti-1422 186 21 . . PROPN dti-1422 186 22 initial initial ADJ dti-1422 186 23 combination combination NOUN dti-1422 186 24 of of ADP dti-1422 186 25 linagliptin linagliptin NOUN dti-1422 186 26 and and CCONJ dti-1422 186 27 metformin metformin NOUN dti-1422 186 28 improves improve VERB dti-1422 186 29 glycaemic glycaemic ADJ dti-1422 186 30 control control NOUN dti-1422 186 31 in in ADP dti-1422 186 32 type type NOUN dti-1422 186 33 2 2 NUM dti-1422 186 34 diabetes diabetes NOUN dti-1422 186 35 : : PUNCT dti-1422 186 36 a a DET dti-1422 186 37 randomized randomized ADJ dti-1422 186 38 , , PUNCT dti-1422 186 39 double double ADJ dti-1422 186 40 - - PUNCT dti-1422 186 41 blind blind ADJ dti-1422 186 42 , , PUNCT dti-1422 186 43 placebo placebo NOUN dti-1422 186 44 - - PUNCT dti-1422 186 45 controlled control VERB dti-1422 186 46 study study NOUN dti-1422 186 47 . . PUNCT dti-1422 187 1 diabetes diabetes NOUN dti-1422 187 2 obes obes PRON dti-1422 187 3 metab metab ADJ dti-1422 187 4 . . PUNCT dti-1422 188 1 2012;14(6):565–574 2012;14(6):565–574 NUM dti-1422 188 2 . . NOUN dti-1422 188 3 20 20 NUM dti-1422 188 4 . . PUNCT dti-1422 188 5 schernthaner schernthaner PROPN dti-1422 188 6 g g PROPN dti-1422 188 7 , , PUNCT dti-1422 188 8 barnett barnett PROPN dti-1422 188 9 ah ah INTJ dti-1422 188 10 , , PUNCT dti-1422 188 11 emser emser VERB dti-1422 188 12 a a NOUN dti-1422 188 13 , , PUNCT dti-1422 188 14 et et PROPN dti-1422 188 15 al al PROPN dti-1422 188 16 . . PROPN dti-1422 188 17 safety safety NOUN dti-1422 188 18 and and CCONJ dti-1422 188 19 tolerability tolerability NOUN dti-1422 188 20 of of ADP dti-1422 188 21 linagliptin linagliptin NOUN dti-1422 188 22 : : PUNCT dti-1422 188 23 a a DET dti-1422 188 24 pooled pooled ADJ dti-1422 188 25 analysis analysis NOUN dti-1422 188 26 of of ADP dti-1422 188 27 data datum NOUN dti-1422 188 28 from from ADP dti-1422 188 29 randomized randomized ADJ dti-1422 188 30 controlled control VERB dti-1422 188 31 trials trial NOUN dti-1422 188 32 in in ADP dti-1422 188 33 3572 3572 NUM dti-1422 188 34 patients patient NOUN dti-1422 188 35 with with ADP dti-1422 188 36 type type NOUN dti-1422 188 37 2 2 NUM dti-1422 188 38 diabetes diabetes NOUN dti-1422 188 39 mellitus mellitus NOUN dti-1422 188 40 . . PUNCT dti-1422 189 1 diabetes diabetes VERB dti-1422 189 2 obes obes PRON dti-1422 189 3 metab metab NOUN dti-1422 189 4 . . PUNCT dti-1422 190 1 2012;14(5):470–478 2012;14(5):470–478 NUM dti-1422 190 2 . . NOUN dti-1422 190 3 21 21 NUM dti-1422 190 4 . . PUNCT dti-1422 191 1 mcgill mcgill PROPN dti-1422 191 2 jb jb PROPN dti-1422 191 3 , , PUNCT dti-1422 191 4 sloan sloan PROPN dti-1422 191 5 l l PROPN dti-1422 191 6 , , PUNCT dti-1422 191 7 newman newman PROPN dti-1422 191 8 j j PROPN dti-1422 191 9 , , PUNCT dti-1422 191 10 et et PROPN dti-1422 191 11 al al PROPN dti-1422 191 12 . . PUNCT dti-1422 192 1 long long ADJ dti-1422 192 2 - - PUNCT dti-1422 192 3 term term NOUN dti-1422 192 4 efficacy efficacy NOUN dti-1422 192 5 and and CCONJ dti-1422 192 6 safety safety NOUN dti-1422 192 7 of of ADP dti-1422 192 8 linagliptin linagliptin NOUN dti-1422 192 9 in in ADP dti-1422 192 10 patients patient NOUN dti-1422 192 11 with with ADP dti-1422 192 12 type type NOUN dti-1422 192 13 2 2 NUM dti-1422 192 14 diabetes diabetes NOUN dti-1422 192 15 and and CCONJ dti-1422 192 16 severe severe ADJ dti-1422 192 17 renal renal ADJ dti-1422 192 18 impairment impairment NOUN dti-1422 192 19 : : PUNCT dti-1422 192 20 a a DET dti-1422 192 21 1 1 NUM dti-1422 192 22 - - PUNCT dti-1422 192 23 year year NOUN dti-1422 192 24 , , PUNCT dti-1422 192 25 randomized randomize VERB dti-1422 192 26 , , PUNCT dti-1422 192 27 double double ADJ dti-1422 192 28 - - PUNCT dti-1422 192 29 blind blind ADJ dti-1422 192 30 , , PUNCT dti-1422 192 31 placebo placebo NOUN dti-1422 192 32 - - PUNCT dti-1422 192 33 controlled control VERB dti-1422 192 34 study study NOUN dti-1422 192 35 . . PUNCT dti-1422 193 1 diabetes diabetes NOUN dti-1422 193 2 care care VERB dti-1422 193 3 . . PUNCT dti-1422 194 1 2013;36(2 2013;36(2 NUM dti-1422 194 2 ): ): PUNCT dti-1422 195 1 237–244 237–244 NUM dti-1422 195 2 . . PUNCT dti-1422 196 1 22 22 NUM dti-1422 196 2 . . PUNCT dti-1422 196 3 groop groop PROPN dti-1422 196 4 ph ph PROPN dti-1422 196 5 , , PUNCT dti-1422 196 6 cooper cooper NOUN dti-1422 196 7 me i PRON dti-1422 196 8 , , PUNCT dti-1422 196 9 perkovic perkovic PROPN dti-1422 196 10 v v NOUN dti-1422 196 11 , , PUNCT dti-1422 196 12 emser emser VERB dti-1422 196 13 a a NOUN dti-1422 196 14 , , PUNCT dti-1422 196 15 woerle woerle PROPN dti-1422 196 16 hj hj PROPN dti-1422 196 17 , , PUNCT dti-1422 196 18 von von PROPN dti-1422 196 19 eynatten eynatten VERB dti-1422 196 20 m. m. NOUN dti-1422 196 21 linagliptin linagliptin ADJ dti-1422 196 22 lowers lower NOUN dti-1422 196 23 albuminuria albuminuria ADV dti-1422 196 24 on on ADP dti-1422 196 25 top top NOUN dti-1422 196 26 of of ADP dti-1422 196 27 recommended recommend VERB dti-1422 196 28 standard standard ADJ dti-1422 196 29 treatment treatment NOUN dti-1422 196 30 in in ADP dti-1422 196 31 patients patient NOUN dti-1422 196 32 with with ADP dti-1422 196 33 type type NOUN dti-1422 196 34 2 2 NUM dti-1422 196 35 diabetes diabetes NOUN dti-1422 196 36 and and CCONJ dti-1422 196 37 renal renal ADJ dti-1422 196 38 dysfunction dysfunction NOUN dti-1422 196 39 . . PUNCT dti-1422 197 1 diabetes diabetes NOUN dti-1422 197 2 care care NOUN dti-1422 197 3 . . PUNCT dti-1422 198 1 2013;36(11 2013;36(11 NUM dti-1422 198 2 ): ): PUNCT dti-1422 198 3 3460–3468 3460–3468 NUM dti-1422 198 4 . . PUNCT dti-1422 199 1 23 23 NUM dti-1422 199 2 . . PUNCT dti-1422 200 1 kamatani kamatani PROPN dti-1422 200 2 n n CCONJ dti-1422 200 3 , , PUNCT dti-1422 200 4 katoh katoh PROPN dti-1422 200 5 t t PROPN dti-1422 200 6 , , PUNCT dti-1422 200 7 sawai sawai PROPN dti-1422 200 8 y y PROPN dti-1422 200 9 , , PUNCT dti-1422 200 10 kanayama kanayama ADJ dti-1422 200 11 h h NOUN dti-1422 200 12 , , PUNCT dti-1422 200 13 katada katada PROPN dti-1422 200 14 n n CCONJ dti-1422 200 15 , , PUNCT dti-1422 200 16 itoh itoh PROPN dti-1422 200 17 m. m. NOUN dti-1422 200 18 comparison comparison NOUN dti-1422 200 19 between between ADP dti-1422 200 20 the the DET dti-1422 200 21 clinical clinical ADJ dti-1422 200 22 efficacy efficacy NOUN dti-1422 200 23 of of ADP dti-1422 200 24 linagliptin linagliptin PROPN dti-1422 200 25 and and CCONJ dti-1422 200 26 sitagliptin sitagliptin NOUN dti-1422 200 27 . . PUNCT dti-1422 201 1 j j PROPN dti-1422 201 2 diabetes diabetes NOUN dti-1422 201 3 endocrinol endocrinol NOUN dti-1422 201 4 . . PUNCT dti-1422 202 1 2013;4(4):5 2013;4(4):5 PROPN dti-1422 202 2 . . PUNCT dti-1422 203 1 24 24 NUM dti-1422 203 2 . . X dti-1422 203 3 alter alter PROPN dti-1422 203 4 ml ml PROPN dti-1422 203 5 , , PUNCT dti-1422 203 6 ott ott PROPN dti-1422 203 7 i i PRON dti-1422 203 8 m m PROPN dti-1422 203 9 , , PUNCT dti-1422 203 10 von von PROPN dti-1422 203 11 websky websky PROPN dti-1422 203 12 k k PROPN dti-1422 203 13 , , PUNCT dti-1422 203 14 et et PROPN dti-1422 203 15 al al PROPN dti-1422 203 16 . . PROPN dti-1422 203 17 dpp-4 dpp-4 NUM dti-1422 203 18 inhibition inhibition NOUN dti-1422 203 19 on on ADP dti-1422 203 20 top top NOUN dti-1422 203 21 of of ADP dti-1422 203 22 angiotensin angiotensin NOUN dti-1422 203 23 receptor receptor NOUN dti-1422 203 24 blockade blockade NOUN dti-1422 203 25 offers offer VERB dti-1422 203 26 a a DET dti-1422 203 27 new new ADJ dti-1422 203 28 therapeutic therapeutic ADJ dti-1422 203 29 approach approach NOUN dti-1422 203 30 for for ADP dti-1422 203 31 diabetic diabetic ADJ dti-1422 203 32 nephropathy nephropathy NOUN dti-1422 203 33 . . PUNCT dti-1422 204 1 kidney kidney NOUN dti-1422 204 2 blood blood NOUN dti-1422 204 3 press press NOUN dti-1422 204 4 res re NOUN dti-1422 204 5 . . PUNCT dti-1422 205 1 2012;36(1):119–130 2012;36(1):119–130 NUM dti-1422 205 2 . . PROPN dti-1422 205 3 25 25 NUM dti-1422 205 4 . . PUNCT dti-1422 206 1 matsuo matsuo PROPN dti-1422 206 2 s s PROPN dti-1422 206 3 , , PUNCT dti-1422 206 4 imai imai PROPN dti-1422 206 5 e e PROPN dti-1422 206 6 , , PUNCT dti-1422 206 7 horio horio PROPN dti-1422 206 8 m m PROPN dti-1422 206 9 , , PUNCT dti-1422 206 10 et et PROPN dti-1422 206 11 al al PROPN dti-1422 206 12 . . PROPN dti-1422 206 13 revised revise VERB dti-1422 206 14 equations equation NOUN dti-1422 206 15 for for ADP dti-1422 206 16 estimated estimate VERB dti-1422 206 17 gfr gfr NOUN dti-1422 206 18 from from ADP dti-1422 206 19 serum serum NOUN dti-1422 206 20 creatinine creatinine NOUN dti-1422 206 21 in in ADP dti-1422 206 22 japan japan PROPN dti-1422 206 23 . . PUNCT dti-1422 207 1 am be AUX dti-1422 207 2 j j PROPN dti-1422 207 3 kidney kidney PROPN dti-1422 207 4 dis dis PROPN dti-1422 207 5 . . PUNCT dti-1422 208 1 2009;53(6):982–992 2009;53(6):982–992 X dti-1422 208 2 . . PROPN dti-1422 208 3 26 26 NUM dti-1422 208 4 . . PUNCT dti-1422 208 5 del del PROPN dti-1422 208 6 prato prato PROPN dti-1422 208 7 s s PROPN dti-1422 208 8 , , PUNCT dti-1422 208 9 barnett barnett PROPN dti-1422 208 10 ah ah INTJ dti-1422 208 11 , , PUNCT dti-1422 208 12 huisman huisman PROPN dti-1422 208 13 h h NOUN dti-1422 208 14 , , PUNCT dti-1422 208 15 neubacher neubacher ADJ dti-1422 208 16 d d NOUN dti-1422 208 17 , , PUNCT dti-1422 208 18 woerle woerle PROPN dti-1422 208 19 hj hj PROPN dti-1422 208 20 , , PUNCT dti-1422 208 21 dugi dugi PROPN dti-1422 208 22 ka ka PROPN dti-1422 208 23 . . PROPN dti-1422 208 24 effect effect NOUN dti-1422 208 25 of of ADP dti-1422 208 26 linagliptin linagliptin ADJ dti-1422 208 27 monotherapy monotherapy NOUN dti-1422 208 28 on on ADP dti-1422 208 29 glycaemic glycaemic ADJ dti-1422 208 30 control control NOUN dti-1422 208 31 and and CCONJ dti-1422 208 32 markers marker NOUN dti-1422 208 33 of of ADP dti-1422 208 34 beta beta NOUN dti-1422 208 35 - - PUNCT dti-1422 208 36 cell cell NOUN dti-1422 208 37 function function NOUN dti-1422 208 38 in in ADP dti-1422 208 39 patients patient NOUN dti-1422 208 40 with with ADP dti-1422 208 41 inadequately inadequately ADV dti-1422 208 42 controlled control VERB dti-1422 208 43 type type NOUN dti-1422 208 44 2 2 NUM dti-1422 208 45 diabetes diabetes NOUN dti-1422 208 46 : : PUNCT dti-1422 208 47 a a DET dti-1422 208 48 randomized randomized ADJ dti-1422 208 49 controlled control VERB dti-1422 208 50 trial trial NOUN dti-1422 208 51 . . PUNCT dti-1422 209 1 diabetes diabetes NOUN dti-1422 209 2 obes obes PRON dti-1422 209 3 metab metab ADJ dti-1422 209 4 . . PUNCT dti-1422 210 1 2011;13(3):258–267 2011;13(3):258–267 NUM dti-1422 210 2 . . PUNCT dti-1422 210 3 http://www.la-press.com http://www.la-press.com X dti-1422 210 4 http://www.la-press.com/drug-target-insights-journal-j23 http://www.la-press.com/drug-target-insights-journal-j23 PROPN